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ABSTRACT 
 Background: Cardiovascular disease (CVD) has emerged as a major cause of 
morbidity and mortality in HIV-infected adults. Research in noninfected populations 
suggests that knowledge of CVD risk factors significantly influences perception of risk. 
Understanding the level of risk factor knowledge and risk perception can inform the 
development of innovative interventions to reduce risk. The purpose of this study was to 
describe cardiovascular risk factor knowledge and risk perception in a cohort of HIV-
infected adults.  
 Specific aims included (a) describing the estimated risk of CVD, the perceived 
risk of CVD, and the level of CVD risk factor knowledge; (b) describing the relationship 
between estimated and perceived risk, and (c) examining the influence of risk factor 
knowledge on perceived risk of CVD. The Health Belief Model was the theoretical 
framework that guided the study.  
 Methods: A prospective observational cohort; cross-sectional design. A 
convenience sample of 130 HIV-infected adults was recruited from two hospital-based 
HIV clinics. Each participant had one study visit in which all data were collected by 
direct interview.  
 Results: Mean age of enrollees was 48 years (SD 8.4); 62% were male; 41.5% 
White, 32% Black, 23% Hispanic; 56% current smokers; mean years since HIV diagnosis 
were 14.7; mean BMI 27 (SD 5.5); 48.5% had prehypertension. Higher scores on the 
Heart Disease Fact Questionnaire indicate a higher degree of knowledge. In this sample, 
the Mean was 19, (S.D. 3.5; range 6–25), indicating a fair degree of knowledge. 
 vii 
Estimated and perceived risk were significantly, though weakly, correlated r (126) = .24, 
p = .01. Controlling for age, risk factor knowledge was not predictive of perceived risk (F 
[1,117] = 0.13, p > .05) 
 Conclusions: HIV-infected adults are at increased risk for cardiovascular disease. 
Traditional CVD risk factors such as smoking, prehypertension, and being overweight are 
highly prevalent. Despite having a fair level of risk factor knowledge, knowledge did not 
influence perception of risk for CVD. Research to improve risk perception and to develop 
innovative interventions that reduce CVD risk is needed for this population. 
 viii 
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CHAPTER 1  
State of the Science 
 Advances in the medical treatment of persons infected with HIV over the past 25 
years have led to an increased lifespan for HIV-infected individuals. In fact, recent 
studies show that mortality rates for HIV-infected persons now mirror that of the general 
population (Bhaskaran et al., 2008; Lewden et al., 2007). Cardiovascular disease (CVD) 
is the leading cause of death in the United States (American Heart Association, n.d.) and 
over the past 7 years, CVD has emerged as a major cause of morbidity and mortality in 
adults with HIV-infection (Gill et al., 2010; Grinspoon, 2005; Lipshultz, Fisher, Lai, & 
Miller, 2003; Sackoff, Hanna, Pfeiffer, & Torian, 2006). A growing body of evidence 
suggests that there is an increased rate of acute myocardial infarction (AMI) in HIV-
infected persons (Currier et al., 2003; Friis-Moller, et al., 2007; Triant, Lee, Hadigan, & 
Grinspoon, 2007). One-third of HIV-infected adults have a greater than 10% risk of 
having a cardiac event within 10 years (Hadigan, et al., 2003). A cross-sectional study of 
over 700 participants found that compared to HIV-negative age- and gender- matched 
controls, HIV-infected participants were twice as likely to have a high predicted 10-year 
risk (>20%) of AMI (Bergersen, Sandvik, Bruun, & Tonstad, 2004). AMI rates per 1,000 
person-years were significantly higher in HIV-infected participants compared to matched 
controls (11.13 vs. 6.98), and the relative risk was 75% higher for those infected with 
HIV (Triant, et al., 2007). In addition, the rate of AMI by age group was significantly 
higher at each age for those infected with HIV when compared to HIV-negative controls. 
Lastly, in a retrospective cohort analysis in New York City, CVD accounted for 23.8% of 
all non-HIV-related deaths in HIV-infected persons (Sackoff, et al., 2006). 
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 The increased incidence of AMI and increased prevalence of CVD in HIV-
infected persons is multifactorial. Recent reports suggest that persons with HIV infection 
have a higher prevalence and degree of premature coronary atherosclerosis compared to 
non-HIV-infected counterparts (Grunfeld et al., 2009; Guaraldi et al., 2009; Hsue et al., 
2004; Kingsley et al., 2008; Lo et al., 2010; Van Vonderen et al., 2009). Traditional risk 
factors for CVD, such as smoking, are more prevalent in this population (Cockerham et 
al., 2010; Friis-Moller et al., 2003; Glass et al., 2006; Kaplan et al., 2007) and may 
contribute to the elevated rate of AMI. Comorbidities, such as hypertension, diabetes, 
dyslipidemia, and obesity, also increase CVD risk. In one cross-sectional study of HIV-
infected adults, more than 40% of men and 60% of women met criteria for being 
overweight or obese with a body mass index of greater than 25 (Kaplan et al., 2007). 
Importantly, however, the traditional risk factors did not completely account for the 
increased rate of coronary events (Lipshultz et al., 2003; Sterne et al., 2007). Chronic 
inflammation related to HIV viral replication and metabolic changes associated with 
antiretroviral therapy may confer additional risk (Hadigan et al., 2003; Kuller et al., 
2008). 
Research in non-HIV-infected populations suggests that knowledge of 
cardiovascular risk factors significantly influences perception of risk (Choi, Rankin, 
Stewart, & Oka, 2008; Christian, Mochari, & Mosca, 2005). However, studies in non-
HIV-infected women demonstrate that women are often unaware of CVD risk factors 
(Hart, 2005; Lange et al., 2009; Oliver-McNeil & Artinian, 2002; Pregler et al., 2009; 
Thanavaro, Thanavaro, & Delicath, 2010; Wu, 2007) and subsequently underestimate 
their risk (Choi et al., 2008; Christian et al., 2005; Hart, 2005). Few studies have explored 
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CV risk factor knowledge or risk perception among HIV-infected adults. Most studies 
have focused on the prevalence of CVD, the actual risk of AMI, and the proposed 
mechanisms of CVD; however, to date the assessment of risk perception and knowledge 
of CVD risk factors has not been studied in the HIV-infected population. The purpose of 
this study was to describe cardiovascular risk factor knowledge and CVD risk perception 
in a cohort of HIV-infected adults. The primary aims of this study were the following: 
1. To describe (a) the estimated risk of cardiovascular disease, using the 
Framingham Risk Assessment Tool, (b) the perceived risk of cardiovascular 
disease, and (c) the level of cardiovascular risk factor knowledge in HIV-
infected adults; 
2. To describe the relationship between estimated and perceived risk of CVD in 
HIV-infected adults; 
3. To examine the influence of cardiovascular risk factor knowledge on 
perceived risk of cardiovascular disease in a sample of HIV-infected adults. 
Background and Significance  
HIV and cardiovascular disease. In the mid-1990s, with the approval of 
protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs), triple 
drug therapy became the standard of care for the treatment of HIV/AIDS. This 
development lead to maximal virologic suppression, and following 1996, mortality due to 
HIV infection decreased dramatically (Bozzette et al., 2008; Sackoff, et al., 2006) 
However, case reports of myocardial infarction in young HIV-infected patients caused 
alarm and spurred investigation (Currier et al., 2008).  
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 Beginning in 2003, several published reports noted that there was an increased 
rate of myocardial infarction in HIV-infected individuals, possibly related to 
antiretroviral therapy. Fris-Moller et al. (2003) published initial data from the Data 
Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study in the New England 
Journal of Medicine (Friis-Moller et al., 2003). This prospective, longitudinal 
observational cohort (N = 23,468) conducted across three continents was designed to 
determine if exposure to antiretroviral therapy (ART) was associated with an increased 
risk of AMI. It was found that ART was associated with a 26% increase in the rate of 
AMI per year of exposure (p<0.001).  
 Other studies had similar findings. Crum et al. (2006), in a retrospective review of 
over 4,000 patients, found that non-HIV-related deaths increased from 8% to 32% from 
the pre-HAART (highly active antiretroviral therapy) to the late-HAART era. In patients 
with a CD4 rate greater than 200, cardiac disease accounted for 13% of deaths (Crum, et 
al., 2006). In a population-based retrospective analysis of death certificates (N = 68,669) 
of HIV/AIDS patients between 1999 and 2004 in New York City, the rate of HIV-related 
deaths decreased overall by 54% (p<0.001); however non-HIV-related deaths increased 
by 32% (p = 0.015) during this same period, and cardiovascular disease accounted for 
over 23% of the non-HIV-related deaths (Sackoff, et al., 2006). 
 A retrospective analysis comparing HIV-infected (n = 3851) and non-HIV-
infected individuals (N = 1,044,589) found statistically significant differences in the rate 
of AMI in these two populations (Triant, et al., 2007). The rate of myocardial infarction 
(MI) was 11.13 per 1,000 person-years for HIV-infected individuals compared to 6.98 
per 1,000 person-years for non-HIV-infected. This difference reflects a relative risk for 
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AMI related to HIV infection of 1.75 (p < .001). These reports further demonstrated the 
changing paradigm of HIV morbidity and mortality and the increased risk of myocardial 
events related to HIV infection and/or its treatment. Noting the increased incidence of 
AMI, investigators began to focus on the prediction of AMI risk using the Framingham 
Risk Score.  
HIV infection and cardiovascular risk. Several cross-sectional studies 
demonstrated that HIV-infected individuals had significant rates of 10-year predicted risk 
for myocardial infarction (MI; Wilson, et al., 1998). Using the standard risk categories 
from the Framingham study, moderate risk was defined as 10–20% risk, and high risk 
was defined as greater than a 20% risk over a 10-year period. Across studies, it was found 
that 14–33% of HIV-infected individuals met criteria for moderate risk of MI (Glass, et 
al., 2006; Hadigan, et al., 2003; Sayler, Lyon, Settle, Elswick, & Rackley, 2006).  
 Three studies compared the rate of MI risk in HIV-infected and non-HIV-infected 
individuals. Saves et al. (2003) found that the risk for MI was higher among HIV-infected 
men (RR 1.20) and HIV-infected women (RR 1.59) as compared to their non-HIV-
infected counterparts (p < .00001 for both; Saves et al., 2003). Similarly, De Socio et al. 
(2007) found that, when comparing 403 HIV-infected persons with 200 age- and gender-
matched non-HIV-infected controls, the mean 10-year predicted risk in HIV-infected 
persons was higher; however it was not statistically significant (p = .32; De Socio, et al., 
2007). Bergersen et al. (2004) reported in a cross-sectional study of 721 subjects that 
compared to non-HIV-infected age- and gender-matched controls, HIV-infected 
participants on ART were twice as likely to have a high (>20%) predicted 10-year risk of 
MI (11.9% vs. 5.3%, p = .004; Bergersen et al., 2004).  
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 Law et al. (2006) used the D:A:D study group data to examine the accuracy of the 
Framingham Risk Equation to predict MI risk in this population (Law et al., 2006) In 
patients on ART, the rate of observed MI was higher than that predicted by the 
Framingham equation at each year of follow-up (1–4 years). The Framingham Risk 
Equation, which is not validated in patients with HIV infection, may underestimate the 
risk of MI in individuals receiving ART. This finding supports that metabolic changes 
caused in part by ART increased the observed rate of MI, or that a mechanism related to 
the medications themselves contributed to the increased rate of MI. The predicted rate of 
MI in patients not receiving ART was similar to or higher than patients who had received 
ART for one year or less, further supporting that continued ART increased MI risk (Law 
et al., 2006).  
 Low CD4 cell count has been implicated as an independent risk factor for 
cardiovascular events (Lichtenstein et al., 2010). In the HIV Outpatient Study (HOPS) 
cohort, a longitudinal analysis of 2005 patients spanning 7 years of follow-up, patients 
who had a CD4 cell count less than 350 had a higher rate of CVD events when compared 
to patients with a CD4 greater than 500 (HR 1.58, CI 1.09–2.30), suggesting an 
attributable risk of approximately 20%. Additionally, traditional CVD risk factors (such 
as smoking, hypertension, and diabetes) and baseline CD4 count less than 500 were 
significantly associated with a higher rate of events (p < .05). Using arterial stiffness as a 
marker of subclinical atherosclerotic disease, Ho et al. (2010) found that a nadir CD4 of 
less than 350 in HIV-infected patients was a predictor of arterial stiffness and was 
associated with increased cardiovascular risk, independent of other risk factors (Ho et al., 
2010). 
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 Traditional risk factors associated with CVD, such as smoking, are more 
prevalent in HIV-infected persons. In the D:A:D cohort, more than 56% of participants 
were previous or current smokers (Friis-Moller, et al., 2003). In both the univariate and 
multivariate models, this conferred a relative risk of 2.08 and 2.17, respectively, for MI 
(p = .007). The Swiss Cohort Study, a 6-year longitudinal study of over 8,000 
participants, found that current smoking was the most common cardiovascular risk factor 
in the cohort, with a reported prevalence of 57% (Glass, et al., 2006). Similarly, Kaplan 
reported a 35–40% prevalence of current smokers in a cross-sectional study of over 4,000 
HIV-infected and non-HIV-infected participants (Kaplan et al., 2007). The difference in 
smoking rates between HIV-infected men (35.5%) and non-HIV-infected men (28%) was 
statistically significant (p < .001). 
 Metabolic changes including hyperlipidemia have been implicated as factors 
associated with elevated cardiovascular risk and increased frequency of cardiac events 
(Aboud et al., 2010; Ford et al., 2010; Friis-Moller et al., 2003; Kotler, 2008; Saves et al., 
2003). Increases in total cholesterol and triglyceride levels were initially reported in 1995 
with ritonavir use and continued to be associated with protease inhibitor therapy 
(Colagreco, 2004). In 2006, Crum et al. compared changes in cause of death from the 
pre-ART to the late-ART era and reported that, in a cohort of over 4,000 participants, 
higher cholesterol levels were noted in the late-ART era (Crum et al., 2006). Saves et al. 
(2003) compared HIV-infected to non-HIV-infected adults and found significantly higher 
levels of total cholesterol and triglycerides in those infected with HIV. This contributed 
to a moderately elevated level of risk for CVD (RR 1.20 for men and RR 1.59 for 
women; p < .00001) when using the Framingham Risk Equation variables in this 
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population (Saves et al., 2003). The Swiss Cohort Study reported higher lipid parameters 
with 35% of participants having elevated triglycerides at baseline screening using the 
National Cholesterol Education Program (NCEP) guidelines (Glass et al., 2006).  
 While lipid changes related to antiretroviral use have been well described, some 
investigators have found that lipid values were altered in HIV-infected patients even prior 
to being exposed to antiretroviral therapy (Baker et al., 2010; El-Sadr et al., 2005). One 
prospective study of 419 patients, which included 20% women, 60% African-American 
and 10% Latino, found that a higher CD4 lymphocyte count was associated with higher 
HDL cholesterol concentration, while higher HIV-RNA levels were associated with 
lower HDL concentrations (p<0.005). In addition, a history of an AIDS-defining event 
was associated with higher total cholesterol, higher VLDL cholesterol, and higher 
triglyceride levels (El-Sadr et al., 2005). 
 The D:A:D Study Group (2003) found that 45% of participants had dyslipidemia 
at baseline (Friis-Moller et al., 2003). Elevated total cholesterol and elevated triglycerides 
were associated with an increased relative risk of 1.16 and 1.39 (p = .01, p = .003, 
respectively) of MI. Both the Swiss Cohort Study (Glass et al., 2006) and the D:A:D 
study (D:A:D Study Group, 2008) reported that the percentage of patients on lipid 
lowering therapy increased steadily over time—tripling in each of the 6-year periods 
reported.  However, both studies found that the 10-year risk for CVD remained steady (as 
in the Swiss Cohort Study) or increased (in the D:A:D Study) despite the increased use of 
these medications. In fact, the number of participants in the D:A:D Study with high CVD 
risk increased from 35% to 41% over the same period (p < .001).   
 9 
 In a prospective study of 121 HIV-infected patients compared with 273 age- and 
gender-matched non-HIV-infected controls, Hadigan et al. (2003) reported that the risk of 
MI was significantly elevated (7.4% vs. 5.3%; p = .002) in those participants with HIV-
associated lipodystrophy when compared to controls (Hadigan et al., 2003). Those 
without lipodystrophy did not have the same finding. Additionally, individuals with 
primary lipoatrophy had the highest overall 10-year risk estimate (9.2%; p = .04) when 
compared to those with lipohypertrophy and mixed lipodystrophy. Lipoatrophy generally 
is defined as a loss of fat in the face or extremities, while lipohypertrophy includes 
increased abdominal girth or increased chest/breast fat. In this study, self-reported fat 
redistribution by the study participants was used as the inclusion criteria. Individuals who 
reported change in more than one area were invited to participate, and body habitus 
changes were confirmed by inspection during the initial study visit.  
 A cross-sectional study of 347 patients found that moderate lipoatrophy or 
moderate lipohypertrophy (OR 4.3; p = .006; OR 2.3; p = .03) was associated with an 
increased odds ratio of having hypertension (Crane, Grunfeld, Harrington, & Kitahata, 
2009). A cross-sectional study of 372 HIV-infected patients on ART found that 
lipoatrophy (OR 3.82), lipohypertrophy (OR 7.65), and mixed lipodystrophy (OR 4.36) 
were strongly associated with coronary artery calcium, a marker for subclinical 
atherosclerosis (Guaraldi et al., 2010). In the general population, visceral adiposity, 
higher BMI, and increased waist circumference are often associated with increased risk 
for cardiovascular disease (Ricciardi, Metter, Cavanaugh, Ghambaryan, & Talbot, 2009). 
 The Strategies for Management of Antiretroviral Therapy (SMART) trial 
randomized 5,472 participants to receive either continuous ART therapy or episodic ART 
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guided by the CD4 cell count (El-Sadr et al., 2006). The primary endpoint for this study 
was development of an opportunistic infection or death. A secondary endpoint was any 
major cardiovascular, renal, or hepatic event. The trial indicated that episodic ART was 
associated with an increased risk of AMI (HR 1.6, 95% CI, 1.0 to 2.5, p = .05). The 
investigators concluded that future research was needed to investigate the effect of 
treatment interruption and intermittent viremia on inflammation and biomarkers and their 
relationship to cardiac events.  
 Two large trials have demonstrated that individual antiretroviral agents are 
associated with an increased risk of MI—the SMART study and the D:A:D trial 
(Lundgren et al., 2008; Sabin et al., 2008). The D:A:D study found that recent use (within 
the preceding 6 months) of abacavir or didanosine was associated with a 90% increase (p 
= .0001) and 49% increase (p = .003), respectively, of rate of MI among the 33,347 
patients enrolled in the study (Sabin et al., 2008). The increased rate was noted while 
patients were taking the drugs and shortly after discontinuing their use; however, the risk 
seemed to diminish within a few months after their discontinuation. No cumulative effect 
was noted. The SMART study findings were consistent with D:A:D with respect to 
abacavir use, finding that the risk of CVD was doubled in patients receiving abacavir 
when compared to other nucleoside backbones (Lundgren et al., 2008). Patients who 
were on abacavir at study entry were also noted to have elevated levels of biomarkers, 
including hsCRP and IL-6, and the investigators suggested that abacavir may have pro-
inflammatory properties. A smaller study of 35 patients also found a significant increase 
in hs-CRP (p = .03) following a switch to an abacavir-containing regimen when 
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compared with patients who received a non-abacavir-containing regimen who served as 
controls (Kristoffersen et al., 2009). 
 Subsequent to the SMART trial findings, investigators began to focus on 
endothelial dysfunction (Baker et al., 2009; Dube et al., 2010; Francisci et al., 2009; Ross 
et al., 2008) and specific biomarkers, including C-reactive protein (CRP), interleukin-6 
(IL-6), D-dimer, s-VCAM, CCL2, adiponectin, and IL-10 (Baker et al., 2010; Calmy et 
al., 2009; Kuller et al., 2008; Ross et al., 2009; Tien et al., 2010; Triant, Meigs, & 
Grinspoon, 2009) to explain the increased CVD risk in this population. Collectively, 
these studies suggest that persistent viremia, immune activation, and inflammation related 
to HIV viral infection and replication may account for some of the increased risk of 
cardiac events seen in the SMART trial.  
 In a nested case control study of the SMART trial participants, Kuller et al. (2008) 
reported that IL-6 and D-dimer levels were higher at study entry and were significantly 
related to all-cause mortality (OR 8.3, 95% CI, 3.3–20.8, p < .0001 and OR 12.4, 95% 
CI, 4.2–37.0, p < .0001; Kuller et al., 2008). Comparing SMART study participants with 
non-HIV-infected controls, Neuhaus et al. (2010) found that hs-CRP and IL-6 levels were 
55% higher in those with HIV infection (p < .001) and remained so even after initiation 
of ART and achievement of virologic suppression (Neuhaus et al., 2010). Triant et al. 
(2009) found that CRP and HIV status were independently associated with AMI even 
after controlling for age, sex, race, hypertension, diabetes, and dyslipidemia (OR 2.13, 
95% CI, 1.92–2.37, p < .0001; and OR 1.93, 95% CI, 1.21–2.93, p = .004; Triant et al., 
2009). These investigators concluded that compared with non-HIV-infected patients with 
normal CRP, those with HIV infection and elevated CRP had a fourfold increase in the 
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risk of AMI. Calmy et al. (2009) concluded that HIV replication was associated with 
increased levels of VCAM and CCL2, and decreased levels of adiponectin and IL-10. 
The associations persisted even after adjusting for known cardiovascular risk factors, 
such as age, total cholesterol, and LDL cholesterol levels (Calmy et al., 2009). This 
cohort consisted of 62% women; however, overall predicted CVD risk was low with 49% 
of the cohort having a Framingham Risk Score of less than 10%.  
 Preclinical atherosclerosis, measured by carotid intima-medial thickness (cIMT), 
has been the focus of several investigations (Calza et al., 2009; De Socio et al., 2010; 
Grunfeld et al., 2009; Hsue et al., 2004, 2006; Maggi et al., 2009; Ross et al., 2009; Van 
Vonderen et al., 2009). A cIMT of greater than 0.9 mm is considered a pathologic 
finding, and the American Heart Association has endorsed the use of cIMT in 
cardiovascular risk assessment (Greenland et al., 2010). Comparing HIV-infected to 
noninfected persons, investigators found that HIV infection was associated with greater 
cIMT (p < .0001), even after adjusting for traditional CVD risk factors and demographic 
variables, and was similar to changes usually seen in smokers (Grunfeld et al., 2009). A 
longitudinal study of 37 ART-naïve patients examined cIMT for 24 months after the 
initiation of ART and found that cIMT increased progressively over time and did not 
differ by regimen prescribed (Van Vonderen et al., 2009). Changes in cIMT in this study 
were statistically significant (p < .001 and p = .01). Calza et al. (2009) found that the 
mean values of cIMT were more elevated in participants who were ART-experienced 
compared to those who were ART-naïve. In addition, the prevalence of carotid plaques 
was higher in those who were ART-experienced, had a longer duration of HIV infection, 
had hyperlipidemia, or had lipodystrophy (Calza et al., 2009). Maggi et al. (2009) found 
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that the presence of subclinical carotid lesions, measured by cIMT, was highly prevalent 
(20.9%) among antiretroviral-naïve subjects. A previous study had reported an increased 
cIMT prevalence of 6.7% in an age-matched HIV-negative control group (Maggi et al., 
2000). This was significantly associated (OR 5.9, 2.1–16.3, p < .006) with participants 
with elevated Framingham Risk Scores (Maggi et al., 2009). De Socio et al. (2010) also 
found that subclinical atherosclerosis in ART-naïve patients was significantly associated 
with elevated Framingham Risk Scores (p < .001). A cross-sectional study examining 
young adults, between the ages of 17 and 23, found that HIV infection itself and duration 
of antiretroviral therapy were both associated with higher cIMT (p < .001; Vigano et al., 
2010).   
 A previous study showed conflicting results—cIMT annual progression rates did 
not differ among HIV-infected participants taking protease inhibitor therapy, those not on 
protease inhibitor therapy, and uninfected controls. This study however included both 
participants on ART and on a treatment interruption; also, use of lipid-lowering therapies 
was not controlled for—these two factors may account for some of the difference 
(Currier et al., 2007). 
 Endothelial function, measured by brachial artery flow-mediated dilation (FMD), 
has been examined in several studies in an attempt to determine the etiology of increased 
cardiovascular risk in HIV infection. These studies included a retrospective analysis 
(Francisci et al., 2009), one prospective analysis (Ross et al., 2008), and one cross-
sectional study (Baker et al., 2009). Across these studies, the data suggest that HIV 
infection itself, and not HIV treatment, induces endothelial activation and endothelial 
dysfunction. These changes may explain some of the association between chronic 
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inflammation seen with HIV viral replication and the increased incidence of MI in HIV 
disease. 
Cardiovascular disease and perceived risk. In the non-HIV-related literature, 
studies demonstrated that women were often unaware of CVD risk factors (Hart, 2005; 
Lange et al., 2009; Oliver-McNeil & Artinian, 2002; Pregler et al., 2009; Thanavaro et 
al., 2010; Wu, 2007) and had low levels of risk factor knowledge (Lange et al., 2009; 
Oliver-McNeil & Artinian, 2002; Thanavaro et al., 2010). Thanavaro and colleagues 
(2006) found in a sample of 120 women that low education level was associated with 
poor CVD risk factor knowledge (Thanavaro, Moore, Anthony, Narsavage, & Delicath, 
2006). Poor risk factor knowledge contributed to underestimation of perceived CVD risk 
in some studies (Choi et al., 2008; Christian et al., 2005; Hart, 2005). In a sample of 143 
adults, Choi et al. (2008) found that higher levels of CVD knowledge were associated 
with higher perceptions of CVD risk (Choi et al., 2008). Another study suggested that 
knowledge of cardiovascular risk factors significantly influenced perception of risk 
(Christian et al., 2005). A population-based survey of 816 adults found that 
socioeconomic status was associated with CVD risk perception (Alwan, William, 
Viswanathan, Paccaud, & Bovet, 2009). No studies have been conducted in the HIV-
infected population to evaluate CVD risk perception or risk factor knowledge. 
Summary 
 The extensive review of the empirical literature examining the association of HIV 
infection and cardiovascular disease clearly indicates that there is an increased risk of 
cardiovascular disease and an increased rate of acute myocardial infarction associated 
with HIV infection and/or its treatment. The prevalence of acute events in HIV-infected 
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individuals appears to be elevated when compared to those of similar ages in the general 
population. Previous research has focused on physiologic measures of cardiovascular 
disease in this population. Investigators remain uncertain about whether the elevated risk 
and rate of disease is due to host factors, viral factors, treatment factors, lifestyle 
behaviors, or a combination of these.  
 To date, there is no published report of the level of knowledge that HIV-infected 
individuals have about cardiovascular risk factors. Additionally, it is not known whether 
HIV-infected persons perceive themselves to be at risk for cardiovascular disease. This 
study provides information about HIV-infected patients’ perception of risk and their level 
of risk factor knowledge. It examines whether relationships exist between individuals’ 
level of risk factor knowledge, perceived risk, and estimated risk of cardiovascular 
disease. 
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CHAPTER 2 
Theoretical Framework 
The purpose of this prospective study was to describe cardiovascular risk factor 
knowledge and CVD risk perception in a cohort of HIV-infected adults. Specifically, this 
study examined the influence of cardiovascular risk factor knowledge on perceived risk 
of cardiovascular disease in a sample of HIV-infected adults. Additionally, it described 
the estimated risk of cardiovascular disease (using the Framingham Risk Assessment 
Tool), the perceived risk of cardiovascular disease, the level of cardiovascular risk factor 
knowledge, and the relationship between estimated and perceived risk of CVD in HIV-
infected adults. The Health Belief Model (HBM) was used as a guide to assess and 
describe the concepts of interest in the study.  
Theory Overview  
The HBM is a psychological model originally developed in 1966 by Irwin 
Rosenstock to identify determinants of health-related behavior. The purpose of the model 
is to explain, predict, and ultimately influence or modify behaviors (Rosenstock, 1974). 
Revisions to the model by Rosenstock and colleagues incorporated evidence from 
research about the role that health motivation, health knowledge, and self-efficacy played 
in behavior change (Rosenstock, Strecher, & Becker, 1988). This predictive model was 
initially designed to identify variables that underlie health-related decisions (related to 
immunization uptake) and assess the likelihood that an individual would adopt certain 
behaviors. Later, researchers used it to examine behavior related to health promotion, 
such as performance of breast self-exam (Janz & Becker, 1984), smoking cessation 
(Conrad, Campbell, Edington, Faust, & Vilnius, 1996), and decisions related to chronic 
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illness management—for example, management of asthma (Becker et al., 1978) and 
hypertension (Jones, Jones, & Katz, 1987; Wen-Wen, Wallhagen, & Froelicher, 2010). 
The theoretical model has been used as a guiding framework for numerous prospective 
and retrospective studies over the past 30 years. 
Assumptions and Antecedents of the Theory 
The Health Belief Model is predicated on two assumptions about human 
behavior: that an individual’s behavior is influenced by (a) the value he/she places on 
achieving a particular goal, and (b) his/her estimate of the likelihood that certain 
behaviors or actions will lead to the achievement of a particular goal (Janz & Becker, 
1984). 
 Antecedents in the HBM are those factors that precede and may determine the 
likelihood of a health action occurring. Individuals must possess sufficient concern about 
the heath issue, such that it is viewed as relevant to them. Individuals must believe that 
they are susceptible to the health issue or condition, so that there is the existence of a 
perceived threat. Individuals must also believe that certain health behaviors will be 
beneficial in reducing or eliminating the threat of the illness or disease (Rosenstock et al., 
1988). 
Concepts of the Model 
 The Health Belief Model incorporates individual perceptions (of susceptibility 
and severity), with modifying factors (such as sociodemographic variables, structural 
variables, and cues to action) to predict the likelihood of taking certain behaviors. There 
are four key concepts described in the original model that are considered independent 
predictors of health-related behavior. They include individual perceptions of 
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susceptibility (risk) and severity (which together comprise perceived threat), perceived 
benefits, and perceived barriers. Cues to action and sociodemographic variables are 
modifying factors that may alter perceptions and influence the likelihood of taking action. 
Structural variables, such as knowledge, are additional modifying factors. Self-efficacy, a 
separate independent variable, and health motivation are additional concepts that were 
added in the 1988 revision of the original model. Rosenstock et al. (1988) explained that 
the original model neglected to include these later concepts because of its focus on 
“circumscribed preventive actions” such as immunization uptake that did not require self-
efficacy, per se (Rosenstock et al., 1988). With a change in focus to include acute and 
chronic illness behaviors, they felt the inclusion of self-efficacy was appropriate. This 
addition broadened the scope of the potential barriers construct and led to the model’s 
ability to account for more variance in clinical studies. 
Concept Definitions 
 Perceived susceptibility is defined as the individual’s assessment of his/her risk of 
getting an illness or condition. Perceived severity is the individual’s assessment of the 
seriousness of the illness or condition and the medical, clinical, and social consequences 
related to this condition. These consequences may include death, disability, pain, effect 
on family or work life, or social relationships. Perceived susceptibility and perceived 
severity are additive and comprise perceived threat. Perceived barriers is defined as the 
individual’s assessment of the obstacles that may interfere with the adoption of the new 
behavior, such as cost, side effects, accessibility, and personality characteristics. Self-
efficacy, or the lack thereof, is considered a potential barrier in the revised model. 
Rosenstock et al. use Bandura’s original definition of self-efficacy—the belief that one 
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can successfully execute the behavior required to produce a desired outcome (Rosenstock 
et al., 1988). Health motivation is defined as the incentive to behave in a particular way, 
with incentive (or reinforcement) defined as the value of a particular object or outcome.  
Perceived benefits is defined as the individual’s assessment of the positive outcomes 
associated with the adoption of the new behaviors. It may also refer to the individual’s 
assessment of the effectiveness that certain behaviors will have in reducing the threat of 
illness or disease. Sociodemographic and structural variables, such as age, gender, race, 
education level, income level, and knowledge, are modifying factors that may affect 
individual perceptions and indirectly influence health-related behaviors. Cues to action 
are events that may be related to the body (such as physical symptoms) or the 
environment (such as media advertising, postcard reminders, information provided, or 
personal experiences) that propel an individual toward behavior change. 
This study examined individual perceptions (including perceived 
susceptibility/risk), and modifying factors (including sociodemographic and structural 
variables and cues to action). Perceived barriers, represented by insurance status, was 
also measured. Perceived severity, perceived benefits, and the likelihood of taking action 
were not explored in this study. See Figure 1. 
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Figure 1. Health Belief Model and CVD Risk (Adapted from Stretcher, V., & Rosenstock, I. M., 
1997) 
 
Utility of the Health Belief Model in Research 
The Health Belief Model is a useful model for nursing research. Elder and 
colleagues (1999) have suggested that the model can be used as a guide or tool to develop 
effective and efficient interventions to facilitate behavior and lifestyle changes in 
patients. Information gained from the assessment of an individual’s level of perceived 
susceptibility and severity of the outcome can be used to frame specific health messages. 
Perceived barriers to behavior change can be assessed so that effective interventions to 
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reduce or eliminate some of these obstacles to change can be developed. Perceived 
benefits of behavior change can be assessed, and these can be incorporated into the 
interventions to reinforce the positive outcomes of behavior change and potentially 
increase motivation to change. Cues to action can be developed as reminders of the 
positive benefits of behavior change or negative consequences related to the lack thereof 
(Elder, Ayala, & Harris, 1999).  
Review of Research Utilizing the HBM   
 Numerous prospective and retrospective studies have examined the utility of the 
HBM to explain health-promoting behavior (Abood, Black, & Feral, 2003; Chiou et al., 
2009; Conrad et al., 1996; Janz & Becker, 1984; Jones et al., 1987; Jones, Weaver, & 
Friedmann, 2007; Wen-Wen et al., 2010; Wilson, Sisk, and Baldwin, 1997). In their 
integrative review of 46 studies that used the HBM as the guiding framework, Janz & 
Becker (1984) found that perceived barriers was most strongly associated with the 
adoption of new behaviors. Perceived susceptibility was also a strong predictor of 
behavior. Perceived severity was the least significant variable in the model when 
examining preventive behaviors but was slightly more predictive in sick role behaviors 
(in chronic illness management). Across studies examining cardiovascular health-
promoting behaviors, perceived barriers and perceived susceptibility were most 
significantly correlated with adoption of new behaviors (Janz, 1988; Janz & Becker, 
1984).  
 More recently, the Health Belief Model has been used as the guiding theoretical 
framework in three studies related to cardiovascular risk factor behaviors in the general 
population (Ali, 2002; Chiou et al., 2009; Jones et al., 2007). Self-efficacy was found to 
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be the strongest predictor of CVD-risk-modifying behaviors, such as taking medications 
regularly and eating a heart-healthy diet, in a cross-sectional study of 156 adults—
explaining 24% of the variance in the study (Chiou et al., 2009). In a second study (which 
did not include self-efficacy as a variable), susceptibility to CVD explained 50% of the 
variance, while knowledge of CVD risk factors explained 19.5% (Ali, 2002). One 
longitudinal intervention study examined the effectiveness of a 5-week heart disease 
prevention program (Jones et al., 2007). This small study (N = 48) measured knowledge 
about heart disease and perceived susceptibility to heart disease before and following an 
educational program. Using the participants as their own controls, they found that 
perceived susceptibility increased significantly (r = -.293; p = .04) following the 
educational intervention. 
 Individual cardiovascular risk factors, such as smoking, elevated cholesterol, and 
hypertension, have been the focus of several studies using the HBM as the theoretical 
framework (Abood et al., 2003; Conrad et al., 1996; Jones et al., 1987; Wen-Wen et al., 
2010; Wilson et al., 1997). Perceived barriers (F[1,118] = 22.9, p < .001) and self-
efficacy (F[1,118] = 28.1,p < .001) were predictors of behavior in a cross-sectional study 
(N = 151) comparing participants and nonparticipants in a blood pressure and cholesterol 
screening program (Wilson et al., 1997). Two longitudinal studies, examining 
hypertension management behaviors and smoking reduction behaviors, found that 
perceived barriers was significantly associated with the behavior change (p < .05). In the 
study of smoking behaviors, perceived barriers and cues to action explained 74% of the 
variance in smoking reduction. Neither of these studies measured self-efficacy.  
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 A frequent criticism of the model is that the variables often correlate weakly with 
behavior and that, in most studies, the effect size was small (all r’s < .21; Armitage & 
Conner, 2000). However, in studies that utilize the HBM, variables are often 
inconsistently measured. Use of nonvalidated instruments, variability in the operational 
definitions of the concepts, and inconsistent measurement of the variables have 
contributed to the inconsistency of the findings (Fleury, 1992; Janz & Becker, 1984). 
Rosenstock attributed the lack of predictability, small effect size, and low levels of 
variance to the exclusion of the self-efficacy variable in earlier studies and explained that 
this finding was the impetus to include self-efficacy in later versions of the model. 
Armitage & Conner (2000) explained that in a review of social cognitive models of 
health behavior studies, self-efficacy is often the dominant predictor of individuals’ 
behavior. Perhaps its inclusion in the model will yield more significant findings. 
 In the HIV literature, studies using the Health Belief Model often examine 
medication adherence or condom use practices (Coleman & Ball, 2009; Cox, 2009; Volk 
& Koopman, 2001). In a cross-sectional study of 223 men and women in Kenya, Volk 
and Koopman (2001) found that only perceived barriers was significantly associated with 
the frequency of condom use in men and women (t = -1.98, p < .05; t = -4.01, p < .001, 
respectively). A measure of self-efficacy was not included in this model. Knowledge 
about HIV/AIDS, identified as a separate independent variable in this study, was 
significantly associated with condom use in men only (t = 1.99, p < .05). 
 Cox (2009) examined predictors of medication adherence in a 5-year prospective 
observational substudy of participants in a large phase III research study comparing daily 
versus thrice-weekly use of trimethoprim-sulfa for the prevention of pneumocystis carinii 
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pneumonia. Self-reported medication adherence was measured by participant and 
clinician assessments at 6 and 12 months. Older age (OR 1.5, 1.1–2.0, p = .005) and 
perceived seriousness of HIV (OR 2.8, 0.3–1.0, p = .04) were significantly associated 
with visit adherence in the study. Of the variables studied, only older age was 
significantly associated with medication adherence (OR 1.7, (1.2–2.5, p = .003). The use 
of creative definitions of the HBM concepts used in this study, the measurement of only 
select variables, and the use of self-reported adherence make the interpretation of this 
study’s finding problematic. 
 The Health Belief Model has been used as a theoretical framework for numerous 
studies over the past 30 years. It was used to guide this study of perceived risk, estimated 
risk, and cardiovascular risk factor knowledge in the HIV-infected population. 
Purpose and Specific Aims 
 The purpose of this study was to describe cardiovascular risk factor knowledge 
and CVD risk perception in a cohort of HIV-infected adults. The primary aims of this 
study were as follows: 
1. To describe (a) the estimated risk of cardiovascular disease, using the 
Framingham Risk Assessment Tool, (b) the perceived risk of cardiovascular 
disease, and (c) the level of cardiovascular risk factor knowledge in HIV-
infected adults; 
2. To describe the relationship between estimated and perceived risk of CVD in 
HIV-infected adults; 
3. To examine the influence of cardiovascular risk factor knowledge on 
perceived risk of cardiovascular disease in a sample of HIV-infected adults. 
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Operational Definitions 
In this study, concepts were operationalized in the following manner: 
1. Perceived Susceptibility to CVD was defined as the individual’s 
perception that he/she was at risk for heart disease as measured by the 
Perception of Risk of Heart Disease Scale; 
2. Perceived Barriers was defined as the obstacles that may influence or 
interfere with the individual’s likelihood to take CVD preventive 
action, as measured by the individual’s health insurance status; 
3. Cues to Action was defined as modifying factors related to individual 
symptoms or their environment that affected their likelihood of taking 
CVD preventive behaviors, as measured by a family history of CVD, or 
a personal history of diabetes, hypertension, or elevated cholesterol; 
4. Sociodemographic and Structural Variables was defined as modifying 
factors that may have affected individual perceptions and indirectly 
influence the adoption of CVD preventive behaviors. Several variables 
were measured, including age, gender, race/ethnicity, education level, 
employment status, and heart disease knowledge (measured by the 
Heart Disease Fact Questionnaire). Additionally, the 10-year estimated 
CVD risk of an individual was measured as a structural variable and 
was calculated using the Framingham Risk Score. 
Perceived Severity, Perceived Benefit,s and the Likelihood of Taking Preventive Action 
were not measured in this study.
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CHAPTER 3 
Methods 
This descriptive study employed a prospective, cross-sectional design to describe 
the level of cardiovascular risk factor knowledge, estimated risk of cardiovascular disease 
and CVD risk perception in a cohort of HIV-infected adults. Each participant had one 
study visit in which all demographic and clinical data were collected and all research 
instruments were completed. The principal investigator (PI) collected all data during the 
study visit by direct interview, and each visit lasted 30 to 40 minutes.  
Sample 
The convenience sample for this study consisted of 130 adult participants 
recruited from two hospital-based HIV clinics, located at the Miriam Hospital and the 
Rhode Island (RI) Hospital. A power analysis was conducted for the analyses planned to 
address specific aims #2 and #3 (Tabachnick & Fidell, 1996). Aim #1 is descriptive only. 
A linear regression analysis was conducted to address specific Aim #3 (one predictor—
CVD risk factor knowledge—and one dependent variable—perceived risk of CVD) with 
three covariates, which required a minimum sample size of 84 subjects assuming an 
effect size of  .15, alpha = .05 and 80% power. This is consistent with the power analysis 
for specific Aim #2 (2-tailed correlation between actual and perceived risk of CVD), 
which suggested that a sample size of 82 subjects would provide 80.3% power to yield a 
correlation of .30 or greater between these variables. 
 A sample of 130 HIV-infected adults were recruited for this study—it was 
assumed that there would be less than 5% missing data due to the interview format used 
for data collection from the two hospital-based HIV clinics. These clinics care for over 
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1,200 HIV-infected adults with an average of 6,000 patient visits annually. The 
accessible population included 30% women, 70% men, 40% Hispanic, 30% Caucasian 
and 30% Black. All patients were 18 years of age or older. The female population 
comprised approximately 30% of the clinic population, and recruitment of 37.7% women 
in the study sample was achieved. 
 Inclusion and exclusion criteria. Participants were eligible for participation in 
this study if they met the following inclusion criteria: (a) males and females age 18 or 
older, (b) HIV-infected per the medical record, (c) able to read and speak English, and (d) 
had the ability to give written informed consent. Participants were excluded if they (a) 
were unable to read and understand English, (b) had an established diagnosis of CVD 
(AMI or CVA) in the medical record, or (c) had a past cardiovascular event (myocardial 
infarction or stroke) or intervention (coronary artery bypass surgery, cardiac stent 
placement, or vascular surgery). The principal investigator (PI) documented the number 
of participants excluded, based on the screening history and the inclusion/exclusion 
criteria. The PI tracked the number of participants who declined participation and 
recorded the reasons for decline. 
Setting 
 The setting for this study was Rhode Island Hospital and the Miriam Hospital. 
These hospitals are located in Providence, RI, approximately four miles apart and are 
unified under Lifespan Corporation, a private nonprofit health care organization. They 
are the major teaching hospitals for Brown University Warren Alpert School of 
Medicine. The two HIV clinics provide care to approximately 1,200 HIV-infected adults 
with diverse cultural and economic backgrounds. The clinics are staffed by eight 
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infectious disease physicians, one nurse practitioner, four nurses, and two clinical social 
workers.  
Procedures 
 Institutional Review Board (IRB) approval was obtained from the University of 
Massachusetts Medical School IRB and the RI Hospital IRB. Participants were recruited 
from the RI Hospital and Miriam Hospital HIV clinics simultaneously beginning in 
March 2011. The PI recruited, enrolled and interviewed participants at the Miriam clinic 
on Mondays and Wednesdays. Participants were recruited and interviewed at the RI 
Hospital site on Wednesdays and Thursdays. Approximately five to ten subjects were 
recruited and interviewed weekly. Enrollment and data collection were completed by 
August 31, 2011. As patients presented for their regularly scheduled appointments, the 
clinic staff (including secretary, nursing assistants, and nurses) informed them of the 
ongoing study. If a patient expressed interest in participating, he/she was then referred to 
the PI for screening. The PI explained to potential participants that the study was 
examining the risk of heart disease in persons infected with HIV and measuring the level 
of knowledge of risk factors for heart disease. The PI discussed the study with 
prospective participants in person in a private exam room within the clinic. At the initial 
appointment, subjects who agreed to participate were read the IRB-approved informed 
consent form. The PI allowed time to answer all questions, and the participant’s level of 
involvement was reviewed with each potential participant. Each participant was asked to 
sign the consent form, and a signed copy was given to each participant. Data collection 
began once the consent process was completed. The face-to-face study visits took place 
in a private room in the clinic and lasted 30 to 40 minutes. Patients who preferred to 
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participate on a day other than their appointment day were scheduled to return on another 
day to complete the screening and enrollment process, sign the informed consent, and 
complete the study visit. Less than 5% of participants preferred to do this. 
 The literature suggested that persons with HIV infection may have low literacy 
(Drainoni et al., 2008; Kalichman et al., 2000), and previous experience with this 
population demonstrated that approximately 10–20% of participants may have had 
difficulty completing self-report instruments. To address this potential barrier to 
participation, we decided to obtain study data by direct interview. To evaluate the 
interview procedure, the study instruments were piloted with nine HIV-infected adults 
prior to general study recruitment to examine the time it would take to complete the 
consent process and complete the study instruments.  
Measures 
 Perception of Risk of Heart Disease Scale (PRHDS). This 20-item instrument 
was developed to measure an individual’s perception of the probability of developing 
heart disease (Ammouri & Neuberger, 2008). It is a self-report scale that takes 
approximately 20 minutes to complete. Each item on the scale has a 4-point Likert scale 
response option ranging from 1 (strongly agree) to 4 (strongly disagree). Item scores may 
be summed for subscales and a total scale score. Higher scores on the overall scale 
indicate increased perception of risk. Subscales include dread risk, risk, and unknown 
risk. Initial testing with a primary care sample of 295 persons greater than 15 years of age 
without heart disease demonstrated internal consistency of .68–.80. Total scale alpha was 
.80. Test-retest reliability was  .61–.76. Construct validity was demonstrated by achieving 
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a significant correlation between the PRHDS and the Health Promotion Lifestyle Profile 
II (r = .20–.39, p < .01). 
 CHD risk factor knowledge. The Heart Disease Fact Questionnaire (HDFQ) is a 
25-item instrument that measures knowledge of major risk factors for the development of 
CVD (Wagner, Lacey, Abbott, de Groot, & Chyun, 2006; Wagner, Lacey, Chyun, & 
Abbott, 2005). Each item on this scale has responses of true, false, or I don’t know. Total 
scale scores are calculated by summing the total number of correct answers and can range 
from 0–25. Higher scores indicate a higher level of knowledge. Good internal consistency 
(Kuder-Richardson r = .77) was demonstrated in a group of 524 ethnically diverse adults 
with diabetes. Test-retest reliability was .89. 
 Cardiovascular risk factors. Fasting lipid parameters and blood glucose levels 
obtained within the previous 12 months were extracted from the medical record. The 
standard of care in the clinics for obtaining this labwork is at least once annually. In the 
case where this data was missing, a reminder was given to the provider so that it could be 
obtained following the clinic visit. Height and weight were measured using the same 
scale within each clinic, and the body mass index was calculated using the National Heart 
Lung and Blood Institute formula (National Heart Lung & Blood Institute, n.d.). The PI 
assessed family history of premature CVD (at age less than 65 years in a mother, or less 
than 55 years in a father) and personal history of diabetes mellitus via self-report during 
the study visit. 
 HIV clinical variables. The most recent CD4 (T cell count), nadir CD4, and HIV 
viral load (HIV-RNA by PCR) were collected from the medical record. All current 
antiretroviral medications being taken were obtained from the medical record.    
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 Framingham risk score. The Framingham Risk Score was calculated using the 
National Heart, Lung and Blood Institute worksheet, which includes the measures of total 
cholesterol, smoking status, high-density lipoprotein, and systolic blood pressure ("Third 
report of the National Cholesterol Education Program (NCEP) expert panel on detection, 
evlauation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) 
final report," 2002). Blood pressure was recorded as the average of three seated 
measurements taken five minutes apart by the PI on a manual mercury 
sphygmomanometer during the study visit (Pickering, 2005). The literature suggests that 
averaging at least two measurements of blood pressure resulted in marked increases in 
the predictability of cardiovascular risk assessments (Bell, Hayen, McGeechan, Neal, & 
Irwig, 2011).  
 The Framingham Risk Score, defined as the percent risk of having a coronary 
event in the next 10-year period, was used to determine each participant’s level of 
estimated risk. This score stratifies individuals into three risk categories: low (less than 
10% risk of having an event in the next 10 years), intermediate (10–20% risk), and high 
(more than a 20% risk). Because diabetes mellitus is considered a cardiovascular risk 
equivalent ("Third report of the NCEP expert panel on detection, evaluation, and 
treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report," 
2002), any participant with a diagnosis of diabetes was categorized as having high risk 
(more than 20%). 
 Sociodemographic variables. Demographic variables, including age (in years), 
gender, educational level (in years), self-reported race and ethnicity, insurance status, 
employment status, and time since HIV diagnosis (in years) were obtained by the PI at 
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the initiation of the study interview session. In order to categorize those on ART, those 
on treatment interruption, those never started on ART, and those taking antihypertensive, 
diabetic, or cholesterol-lowering medications, a complete medication list was obtained 
from the medical record. 
Data Management 
 Each participant was assigned a unique research ID number. A master sheet with 
participant names and matched study ID numbers was kept in a locked cabinet in the PI’s 
office. All study data sheets were kept in the locked cabinet, and only the PI had access to 
the data. Only de-identified data were kept on a password protected research designated 
drive at the University of Massachusetts Medical School, which was backed up nightly. 
The PI entered the de-identified data into the database. A research assistant was trained 
and entered all de-identified data into a second identical database. Double entry was 
performed to ensure the accuracy of the data to be analyzed. The two data sets were 
merged, and correlations were run on each variable to identify errors in data entry. Any 
variable that did not have a correlation of one (1) was identified. The data sets were then 
reviewed line by line, and errors in entry were corrected. Correlations were rerun 
between the two data sets to ensure that all errors had been corrected. A clean data set file 
was established, and this data set was used for the remainder of the data analyses for the 
study.  
Data Analysis 
 Descriptive statistics (frequencies, means, standard deviations, and percentages) 
were calculated on the final corrected data set for all study variables. For continuous 
variables, mean, median, skewness, standard error of the mean, standard deviation, and 
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histograms were calculated. Frequencies were run on all categorical variables. All 
continuous variables were checked for normal distribution by calculating Fisher’s 
measure of skewness. A log transformation was performed on the Framingham Risk 
Score variable to achieve a normal distribution.  
 Eleven items in the Perception of Risk of Heart Disease (PRHD) scale were 
reverse coded as they were negatively worded items in the scale. Total scale scores were 
then calculated for each case. The reliability of this scale was calculated by running the 
Cronbach’s alpha coefficient. All responses in the Heart Disease Fact Questionnaire were 
recoded to indicate whether the item had been answered correctly or incorrectly by the 
participant. The response for each item in the scale was dichotomized into a new variable 
indicating correct or incorrect response for that item. A total scale score was calculated 
by summing the number of correct responses. Internal consistency was calculated for the 
Heart Disease Fact Questionnaire using the Kuder-Richardson formula. 
To address Aim #1, the actual (estimated) risk of cardiovascular disease was 
calculated using the Framingham Risk Assessment Tool and was entered as a continuous 
variable. The perceived risk of CVD (measured by the PRHD scale) was calculated and 
entered as a continuous variable. The level of cardiovascular risk factor knowledge, 
measured by the HDFQ, was also summed and entered as a continuous variable. 
Descriptive statistics were run on these variables to describe the sample. 
To describe the relationship between estimated and perceived risk of CVD (Aim 
#2), Pearson correlation statistic was used. The effect of age on risk perception was 
controlled for in the data analysis by running a partial correlation between estimated and 
perceived risk while using age as a covariate in the statistical model. 
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  To examine the influence of cardiovascular risk factor knowledge on perceived 
risk of cardiovascular disease (Aim #3), linear regression was used. Pearson r was used to 
examine the relationship between age, education level, and time since HIV diagnosis with 
risk perception and risk factor knowledge. T-test statistic was used to examine 
differences by gender and ART status. Chi square statistic was used to examine 
differences by race and ethnicity. These tests were performed to determine which 
variables would be included as covariates in the regression equation.   
 Statistical significance was accepted at the 95% confidence interval (p < .05 
level). All statistical analyses were performed using the Statistical Package for the Social 
Sciences Version 17.0 (SPSS) program. 
Protection of Human Subjects  
This cross-sectional study recruited 130 participants from the Miriam and Rhode 
Island Hospital HIV clinics. All visits took place in a private exam room within the HIV 
clinics at each hospital. The study protocol was reviewed and approved by the Rhode 
Island Hospital Human Subjects Committee (IRB) and the University of Massachusetts 
Medical School IRB. All efforts were made to fully explain the study procedures with 
written informed consent obtained prior to enrollment. Every effort was made to protect 
each participant’s confidentiality and minimize risk.  
Human subjects involvement and characteristics. Participants were both male 
and female adults with HIV infection recruited from the two hospital-based HIV clinics. 
Participants were recruited as they presented to their clinic appointments. All subjects 
were at least 18 years of age and reflected the diverse sociodemographic composition of 
the clinic population. The patient demographics of the clinics was 70% male, 30% 
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female, 40% Hispanic, 30% Caucasian, and 30% Black. Ethnicity and gender were not 
used as criteria in determining eligibility. 
Eligible subjects met the following criteria: 
1. Males and females over age 18 
2. HIV-infected per the medical record 
3. Able to read and speak English  
4. Ability to give written informed consent  
Participants were excluded for these criteria: 
1. Inability to read and understand English 
2. Established diagnosis of CVD (acute myocardial infarction or stroke) 
3. Past cardiovascular intervention (coronary artery bypass graft surgery, stent      
placement, or vascular surgery) 
Sources of Research Materials 
The following data were collected from human subjects for research purposes: 
1. A 20-item instrument, Perception of Risk of Heart Disease Scale, was 
completed during the study visit to measure the participant’s perception of his/her 
probability of developing heart disease. 
2. A 25-item instrument, the Heart Disease Fact Questionnaire, was completed 
during the study visit to measure the participant’s cardiovascular risk factor 
knowledge. 
3. Blood pressure measurements were taken three times by the PI during the 
study visit at 5-minute intervals. 
 36 
4. Height and weight were measured for each participant once during the 
study visit. 
5. Demographic data, including age, gender, race/ethnicity, number of years 
diagnosed with HIV, number of years of education, smoking status, presence of 
diabetes, and family history of cardiovascular disease (myocardial infarction history 
in mother or father of participant) were collected by self-report. Current medications 
and most recent lab values (including CD4 count, nadir CD4, glucose and lipid 
values) were obtained from the medical record. Data extraction for demographic and 
laboratory information complied with Health Insurance Portability and Accountability 
Act of 1996 (HIPPA) regulations. 
Potential Risks 
There were no anticipated physical risks to participants. No participants became 
upset when talking about cardiovascular risk factors, however, some participants asked 
about their own level of risk, and these questions were referred back to the participants’ 
medical provider. To guard against the potential for a loss of confidentiality during study 
instruments completion, a unique research ID number was the only identifier entered on 
the data collection instruments. The data were stored in a secure locked cabinet, which 
was accessible only to the PI.  
Adequacy of Protection Against Risks  
Participants were recruited from the Miriam Hospital and Rhode Island Hospital. 
Prior to recruitment, an informational meeting at each outpatient clinic was held to 
explain the study in detail to the clinicians and receptionists. The clinician or staff 
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directed all interested patients to the PI, who was present in the clinic on specified days 
for recruitment and enrollment. If a patient was interested in the study, the PI was 
available to proceed through the enrollment process while the patient was in the clinic. 
Any patient who expressed interest in the study on an alternate day was given a time to 
return on a day when the PI was present in the clinic. 
The PI discussed the study with potential participants in person in a private office 
that was separate from other clinic patients and identified herself as the principal 
investigator of the study. The nature of the study was explained as well as the voluntary 
nature of participation. Each potential participant was reassured that participation, or lack 
thereof, would not influence their medical care. Subjects agreeing to participate were 
asked by the PI to sign an IRB-approved written informed consent. The consent was 
obtained from each participant only after she/he acknowledged understanding of the 
study and expressed willingness to participate. This was done prior to any study 
participation. The informed consent form addressed the purpose of the study, the study 
procedure, risks, confidentiality of materials, right to withdraw from the study at any 
time, and names of study contacts (i.e., the PI, and Human Subjects Committee) in case 
of any concerns or questions. Given the low literacy rates in this population, the PI read 
and explained the form to every potential subject, unless the subject insisted on reading it 
him- or herself. 
 Protection Against Risk  
All study participants were monitored for risks related to study participation. 
Before participating in research assessments, participants were assured of confidentiality, 
and they were told that they had the right to terminate the interview at any time or could 
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refuse to answer specific questions. No participant became distressed, upset, or 
uncomfortable during assessments, and no interviews needed to be terminated. 
 Every precaution was taken to insure that all data were kept strictly confidential. 
Only the PI had access to identifiable data (a list that links the study ID with the 
participants’ names), which was stored in a locked file cabinet in the PI’s office. Personal 
identifiers were stripped from the data and kept separately in a locked file available only 
to the PI. All information provided by a participant was referenced to a unique participant 
ID number and was kept in a locked file cabinet. The participant’s ID number could be 
connected to the participant’s name only through a single master file, accessible only to 
the PI. Passwords and protection codes were used to protect data files against inadvertent 
change or unauthorized access. All data files were backed up nightly. 
 Documentation of data management procedures was carefully maintained. No 
results were reported in a personally identifiable manner; only grouped data were 
presented in publications or presentations, and the usual standards for medical 
confidentiality were observed.  
 Potential Benefits of the Proposed Research to the Subjects and Others  
There were no direct benefits to individual subjects in this study. However, all 
participants were compensated with a $20 retail gift card as compensation for their time 
and participation. 
Importance of Knowledge Gained 
Knowledge gained from this study has the potential to greatly improve treatment 
services for the population of HIV-infected adults. Cardiovascular disease is a major 
cause of morbidity and mortality for this population and this study highlighted knowledge 
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deficits that exist regarding cardiovascular risk and risk factor knowledge. Innovative 
education programs could be developed to address this need. Finding ways to effectively 
reduce cardiovascular risk in the HIV-infected population is of critical importance to the 
promotion of health in this group, especially given the increased life span of HIV-
infected individuals in the U.S.  Finding ways to prevent disease and promote health is 
consistent with the goals of the Institute of Medicine and National Institute of Nursing 
Research. 
Inclusion of Women 
Women were actively recruited into this study. The female population comprised 
approximately 30% of the clinic population, and recruitment of 37.7% women was 
achieved. No one was excluded from participation in this project on the basis of gender. 
Differences were analyzed between males’ and females’ CVD knowledge and perception 
of CVD risk to determine any trends in the data. 
Inclusion of Minorities 
Recruitment of an ethnically diverse group of participants was a high priority, and 
the PI actively recruited minorities into this study. The minority composition of the study 
population was anticipated to be approximately 50% of the total study sample, which is 
reflective of the general clinic population. The state of RI’s population is 12.3% African 
American and 12.5% Hispanic; however, the proportion of African Americans and 
Hispanics in the clinic population is higher. Thus it was expected that minorities would 
be well represented in the study sample. This study may have limited power to 
differentiate CVD knowledge level and perception based on ethnicity or race. However, 
an exploratory analysis of these variables was planned.  
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Inclusion of Children 
This study included individuals age 18 and older. Children under age 18 were not 
recruited because cardiovascular disease related to atherosclerosis and metabolic changes 
is rare in the pediatric population. 
Summary 
Describing HIV-infected patients’ level of cardiovascular risk factor knowledge, 
perceived risk, and actual (estimated) risk is an important initial step in planning 
interventions to reduce risk. Ultimately, examining these concepts and describing the 
relationships among them will lead to insight regarding the needs of this population.
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CHAPTER 4  
Results 
This chapter contains the findings from the pilot study and all descriptive data and 
analyses related to the main study. Following the discussion of the pilot, the reminder of 
the chapter will be organized and presented by specific aims. Descriptive statistics will be 
presented to fully describe the sample studied. Correlations will be presented to examine 
relationships between the variables. Finally, the results of the linear regression model are 
presented to describe the predictive relationship between risk factor knowledge and 
perceived risk. 
Pilot Study 
In March 2011, the first nine participants were recruited and the study interview 
and instruments were piloted to evaluate the (a) study procedures, (b) informed consent 
process, (c) instruments to be used, and (d) time needed to complete the process with 
each participant.  
The study interview lasted 30–40 minutes, which included the time to complete 
the informed consent process, collect the demographic data, and complete the study 
instruments with each participant. Following the interview, an additional 20 minutes were 
required of the PI to extract the laboratory values and the medication lists from the 
medical record.  
The consent form was read to all participants and no revisions were needed. 
Several participants did not want to take home a copy of the consent form and this was 
recorded. The demographic and clinical data collection form was well organized for data 
collection and was without problems. The Heart Disease Fact Questionnaire was easy to 
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understand for participants, and no issues were identified related to the completion of this 
instrument.  
Participants identified that the Perception of Risk of Heart Disease Scale lacked 
an “I don’t know” response option. It was also noted that one item in this scale contained 
the word “unattainable,” which was not understood by seven of the nine (78%) pilot 
participants in the study.  
Following discussion with the committee chair, the PI decided to pilot an alternate 
risk scale, and it was administered to four participants. The Index of Perceived Risk, 
developed by Becker & Levine (1987), was chosen. The index was comprised of four 
items that used a Likert scale from one (1) to five (5); 1 indicated no concern at all, or 
very low probability estimates of having an event, and 5 indicated very high level of 
concern and extremely high estimate for having an event. The items in this scale 
addressed a person’s (a) frequency of concern over having a coronary heart disease event, 
(b) estimate of having an event in the next five years, (c) likelihood of having such an 
event in his/her lifetime, and (c) estimated coronary heart disease risk compared to people 
of the same age and gender in the general population. The fourth item offered responses 
of much less, less, about the same, more, and much more. Items on this scale were 
summed, and the potential range of perceived risk index was four (4) to twenty (20) 
points. A higher score on this scale indicated a higher level of risk. Internal consistency 
of this scale had a published alpha of .80.  
The Index of Perceived Risk was administered to three male and one female 
participant. Response was mixed to this new scale: One participant reported that the 
original scale was “more thorough” and felt the second scale “was just guessing 
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numbers.” A second male participant said “both (scales) were easy,” and the female 
participant said “it doesn’t matter, either one was okay.” The range of education of these 
four participants was from 8 to 12 years. After discussion with the dissertation committee 
members and chair, it was decided that the original Perception of Risk of Heart Disease 
scale would be used and the PI would leave missing any item that participants did not 
know how to respond to and would explain that “unattainable” was similar to the word 
“unreachable.” This explanation was consistently used when any participant expressed 
difficulty understanding this word.  
Aim #1—Descriptive Data 
Sociodemographic variables. During the 6-month recruitment period, 170 HIV-
infected adults were screened and 130 were enrolled. Demographic and clinical 
characteristics of the enrolled participants are presented in Table 1 and Table 2. Mean age 
of the sample was 48.0 (SD±8.4) years; 62% were male, and 69% identified as currently 
unemployed. Race and ethnicity was self-reported with 41.5% as White, 32% Black, 23% 
Hispanic, 1% Asian, and 2% Native American. Mean years of education completed were 
11.8 (SD± 2.7) years. 
 
Table 1  
Sample Demographics of Continuous Variables (N = 130) 
 Mean (± SD) Median Range 
Age (years) 47.9 (8.4) 49.0 22–67 
Years since HIV diagnosis 14.6 (7.9) 15.0 1–30 
Body Mass Index (BMI) 26.7 (5.5) 26.1 14.9–47.8 
Years of Education 11.8 (2.7) 12.0 4–19 
Framingham Risk Score  7.87 (6.0) 6.0 1–25 
Heart Disease Fact Questionnaire 19.0 (3.5) 20.0 6–25 
Perceived Risk of HD scale 53.1 (5.8) 53.0 27–68 
________________________________________________________________________ 
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Table 2 
Sample Demographics of Categorical Variables (N = 130) 
_________________________________________________________________  
               n        (%)  
Male gender 81 62.3% 
Employment status (unemployed) 90  69.2% 
Race/Ethnicity 
  White 
  Black 
  Hispanic 
  Other 
 
54  
42  
30  
4 
 
41.5% 
32.3% 
23.1% 
3.1% 
Hypertension Stage 
  Normal 
  Pre-Hypertension 
  Stage 1 Hypertension 
  Stage 2 Hypertension 
 
43 
63 
22 
2  
 
33.1% 
48.5% 
16.9% 
1.5% 
Type of ART Regimen 
  NNRTI-based 
  PI-based 
  Nuc-sparing 
  Other type of regimen 
  Not on ART 
 
47 
54 
5 
8  
16  
 
36.2% 
41.5% 
3.8% 
6.2% 
12.3% 
Hepatitis C antibody positive 63  48.5% 
Current smoker  73 56.2% 
Involved in smoking cessation 10 7.7% 
Never discussed CVD risk with HCP 99  76.2% 
_________________________________________________________________ 
Of those screened but not enrolled (N = 40), the mean age was 51.0 (SD± 9.3) 
years, not significantly different from the study sample (p = .05). With respect to gender 
and ethnicity, 67.5% who did not participate were male and 52.5% were Hispanic.  
Of the 40 individuals who were screened but did not participate, 32 (80%) were 
ineligible to participate and eight (20%) declined to participate due to a lack of time or 
interest. Of those who were ineligible (N = 32), sixteen (50%) did not speak and 
understand English, and sixteen (50%) had an existing diagnosis of CVD or had a history 
of a prior event, including a myocardial infarction, stroke or an intervention such as a 
coronary artery bypass graft.  
 45 
Clinical variables. Mean years since diagnosis with HIV infection was 14.7 
(SD± 7.9) years. Eighty-seven percent (87%) of the sample was currently taking 
antiretroviral (ART) medications, and 8.5% reported being naïve to treatment. Of those 
taking ART, 36.2% were taking a non-nucleoside reverse transcriptase inhibitor-based 
regimen and 41.5% were taking a protease inhibitor-based regimen. Mean CD4 count 
was 546 (SD± 292), and mean nadir CD4 was 195 (SD± 142). An undetectable HIV viral 
load was noted in 71.5% of participants. Clinical care was covered by publicly funded 
insurance for 68% of participants. A positive Hepatitis C antibody was noted in 49% of 
the study sample. Slightly more than 12% of participants were receiving methadone or 
suboxone maintenance therapy for opioid dependence.  
Clinical and demographic variables, including age, smoking status, hypertension, 
and discussion of CVD with a health care provider, were examined for differences based 
on gender. No significant differences were found, as noted in Table 3. 
Table 3 
Gender Differences in Key Variables (N = 130) 
 
Variable Males n = 81  
(Mean±  SD) 
Females n = 49 
(Mean±  SD) 
p 
Age 48.2 (8.8) 47.6 (7.6) .69 
Heart Disease Fact 
Questionnaire 
 
19.1 (3.5) 
 
18.7 (3.5) 
 
.57 
Perceived Risk of Heart 
Disease 
 
53.3 (5.9) 
 
52.9 (5.7 
 
.67 
 
N (%) N (%) !2 (p) 
Current Smoker 45 (55.6%) 28 (57.1%) .03 (.86) 
Pre-Hypertension 44 (54.3%) 19 (38.8%) 1.7 (.43) 
Discussed CVD with HCP 21 (25.9%) 9 (18.4%) 5.1 (.16) 
________________________________________________________________________ 
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Cardiovascular risk factor variables. Mean total cholesterol of the sample was 
170 (SD± 36) and mean LDL was 97 (SD± 33). Mean HDL was 44 (SD± 17). Mean 
fasting glucose was 96 (SD± 25). Fifty-six percent (56%) of participants self-identified as 
current smokers, with a mean number of cigarettes per day of 10 (SD± 6.8), for a mean 
27 (SD± 12.3) years of smoking. Less than 8% of participants reported being involved in 
smoking cessation efforts at the time of the interview. Only 7% of participants reported 
that they were taking a daily aspirin, and 10% were diagnosed with diabetes mellitus. 
Eleven (8.5%) participants were currently taking a prescription statin medication. When 
asked if they had ever discussed cardiovascular disease with their health care provider, 
76.2% responded negatively. A family history of heart disease in a father (defined as 
myocardial infarction before age 55) was reported by 11.5% and heart disease in a 
mother (defined as myocardial infarction prior to age 65) was reported by 16.2%. Mean 
BMI was 27 (SD± 5.5) with 58.5% of participants in the overweight category (BMI > 
25). When categorizing blood pressure measurements according to the JNC7 
classification categories, 48.5% of participants had a blood pressure reading within the 
prehypertension range, defined as a systolic blood pressure between 120 and 139 or a 
diastolic blood pressure between 80 and -89 (National Heart Lung And Blood Institute, 
2010). 
Framingham Risk Score. The mean Framingham Risk Score (estimated risk) 
was 7.9 (SD ± 6.0) with 67%, 21%, and 12% of participants scoring in the low-, 
moderate-, and high-risk categories, respectively. 
Perception of Risk of Heart Disease Scale (PRHDS). After imputing means for 
9 missing items, the mean total score on the PRHDS was 53.1 (SD ± 5.9). Possible range 
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of this scale score was 20–80. A Cronbach’s alpha of .78 demonstrated good internal 
consistency of the scale when used with this population.  
CHD risk factor knowledge. The mean score on the Heart Disease Fact 
Questionnaire (HDFQ) was 19 (SD± 3.5). The possible range of scores on this scale was 
0–25. Using the Kuder-Richardson formula to examine internal consistency, the scale 
demonstrated good reliability (.74). It was noted that 126 (97%) of participants knew that 
smoking was a risk factor for heart disease; however, only 86 (66%) of participants knew 
that older age was associated with an increased risk of heart disease and only 33 (25%) 
understood the gender differences in CVD risk. Table 4 presents the responses that were 
answered correctly most and least often on the HDFQ. 
Table 4 
Five Questions on Heart Disease Fact Questionnaire Answered Correctly Most and 
Least Frequently (N =130) 
________________________________________________________________________ 
Number (%) who correctly 
                                                                                                                   answered question 
Five questions correctly answered most often: 
   Being overweight increases a person’s risk for heart disease  127 (97.7%) 
   Smoking is a risk factor for heart disease     126 (96.9%) 
   Eating fatty foods does not affect blood cholesterol levels   120 (92.3%) 
   High cholesterol is a risk factor for developing heart disease  119 (91.5%) 
   Regular physical activity will lower a person’s chance of  
    getting heart disease       118 (90.8%) 
Five questions correctly answered least often: 
   The older a person is, the greater their risk of having heart  disease  86 (66.2%) 
   People with diabetes rarely have high cholesterol    77 (59.2%) 
   If your good cholesterol (HDL) is high you are at risk for  
    heart disease        48 (36.9%) 
   People with diabetes tend to have a low HDL (good) cholesterol  77 (59.2%) 
   Men with diabetes have a higher risk of heart disease than women  
  with diabetes        33 (25.4%) 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
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Aim #2—Relationship Between Estimated and Perceived Risk of CVD 
Descriptive statistics were computed for the Framingham Risk Score and these 
data were found to be significantly skewed (Fisher’s measure of skewness = 4.40). 
Therefore these data were transformed using a log transformation to achieve a normal 
distribution. The Perception of Risk of Heart Disease scale scores were normally 
distributed. A significant, though weak, positive correlation was found (r [126] = .24, p = 
.01) between estimated and perceived risk of heart disease. A partial correlation was run 
between estimated and perceived risk while controlling for age and a similar positive 
correlation was noted, r (126) = .22, p < .05.  
The study sample was divided into two subgroups by age to examine whether 
participants greater than 40 years of age had a stronger correlation between estimated and 
perceived risk than those less than or equal to 40 years of age. Interestingly, for the over-
40 age group, the correlation was weaker,  (r [100[ = .19, p = .06), but the correlation for 
participants 40 years or less became stronger (r [26] = .41, p = .03). 
A significant, strong positive correlation was noted between age and estimated 
risk, r (126) = .57, p < .01. No significant relationship was found between age and 
perceived risk, r (130) = .112, p = .20. 
Aim #3—Influence of CVD Risk Factor Knowledge on Perceived Risk of CVD 
To examine the influence of CVD risk factor knowledge (predictor variable) on 
perceived risk of CVD (outcome variable) while adjusting for covariates, linear 
regression was used. The model assumptions for regression were satisfied. The 
scatterplot for perceived risk and risk factor knowledge was linear in distribution. The 
assumptions of normally distributed residuals were met based on the bell-shaped 
 49 
histogram. The K-S statistic was not statistically significant (p = .79) consistent with 
normally distributed residuals. Also, there did not appear to be any influential 
observations (Cook’s distance < 1). Controlling for age, risk factor knowledge was not 
predictive of perceived risk (F [1,117] = .130, p > .05).  
To determine which covariates would be entered into the linear regression model, 
correlations were run to examine for potential relationships between the demographic 
variables and perceived risk of CVD and CVD risk factor knowledge. When these were 
examined, there were no significant relationships found between age, years since HIV 
diagnosis, or years of education, and perceived risk of CVD and CVD risk factor 
knowledge. Correlation statistics and corresponding p values are listed in Table 5. 
Table 5 
Correlation Matrix Between Perceived Risk of CVD, Risk Factor Knowledge, and 
Demographic Variables (N = 130) 
 
Variable   Age  Years of education Years since HIV DX     
                     Pearson Correlation 
Perceived risk of CVD .110   .040   .002 
 P value   .20   .64   .98 
________________________________________________________________________
               Spearman’s Rho Correlation 
Risk factor knowledge .09   .14   .11 
 P value   .27   .09   .21 
 
An independent samples t-test was conducted comparing the mean score of the 
Heart Disease Fact Questionnaire of participants by gender. No significant difference was 
found between male participants (M = 19.13, SD = 3.56) and female participants (M = 
18.77, SD = 3.56), (t [128] = -.559, p = .57). Also, when comparing risk factor 
knowledge by HIV medication status, there was no significant difference in HDFQ scores 
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between those currently taking ART (M =18.97, SD = 3.6) and those who took ART in 
the past (M = 19.1, SD = 1.1), (t [117] = -.13, p = .89) or between those currently taking 
ART and those who were naïve to ART (M = 19.1, SD = 4.0), (t [122] = .18, p = .85).  
A Chi-square test of independence was calculated to compare scores on the Heart 
Disease Fact Questionnaire by race and ethnicity. No significant relationship was found 
(!2(64) = 78.95, p > 0.05).  
Similarly, an independent samples t-test was conducted comparing the mean 
scores on the Perception of Risk of Heart Disease scale by gender. No significant 
difference was found (t [130] = -.42, p = .67). The mean score of female participants (N = 
49) was (M = 52.8, SD = 5.71), and this was not significantly different from the mean 
score of male participants (N = 81), (M = 53.3, SD = 5.97). Also, when comparing 
perceived risk by HIV medication status, there was no significant difference in PRHDS 
scores between those currently taking ART (M = 53.0, SD = 6.0) and those who took 
ART in the past (M = 51.1, SD = 1.8),  (t [119] = .76, p = .44) or between those currently 
taking ART and those who were naïve to ART (M = 54.7, SD = 4.8), (t [124] = .86, p = 
.39).  
The scores on the Perception of Risk of Heart Disease Scale were compared by 
education category using a one-way ANOVA. Participants’ education level was 
recategorized as being less than a high-school (HS) graduate (n = 54, 41.5%), HS 
graduate (n = 36, 27.7%), or having some college education (n = 40, 30.8%). No 
significant difference between groups was found (F [2,127] = 1.2, p = .29). The 
participants who had less than a HS graduate degree (M = 52.1, SD = 6.1) did not differ 
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significantly from those with a HS degree (M = 53.7, SD = 4.2) or those with some 
college level education (M = 53.8, SD = 6.6) on their PRHDS scores. 
 Additionally, the Chi-square test of independence was calculated to examine for 
differences on the Perception of Risk of Heart Disease scale by race and ethnicity, and no 
significance relationship was found (!2[132] = 97.7, p > .05). 
Since there was a significant level of current smoking in this cohort (56%), the 
Perception of Risk of Heart Disease and CHD Risk Factor Knowledge scale scores were 
examined for differences based on smoking status. Using the independent samples t-test 
statistic, no significant difference on the PRHDS was found (t [130] = -1.95, p = .053). 
The mean score of smokers (N = 73) was (M = 54.0, SD = 5.54), and this was not 
significantly different from the mean score of nonsmokers (N = 57), (M = 52.0, SD = 
6.10). Additionally, when examining the HDFQ scale scores by smoking status, no 
significant differences were found (t [130] = .05, p = .96). The mean score of current 
smokers on the HDFQ was (M = 18.9, SD = 3.60), and this was not significantly different 
from the mean score of nonsmokers (M = 19.0, SD = 3.51). 
Summary of Results 
Results of this study demonstrated that HIV-infected patients have a high 
prevalence of cigarette smoking, a major traditional risk factor for cardiovascular disease. 
However, very few were involved in cessation efforts, and a majority reported that they 
had not discussed CVD risk with their health care providers. Almost half of the 
participants had a BMI consistent with being overweight. Most patients were taking 
antiretroviral therapy and had an undetectable viral load, indicating good ART adherence. 
Mean T cell count was above 500, demonstrating good immune reconstitution; and, this 
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clinical indicator is associated with a lower risk of morbidity and mortality due to HIV 
infection, thus highlighting the importance of addressing co-morbidities in this 
population. 
Nearly half of the participants had a mean systolic or diastolic blood pressure 
reading consistent with a diagnosis of prehypertension. One-third of the sample had more 
than a 10% risk of having a cardiovascular event in the next 10 years, as demonstrated by 
the Framingham Risk Score. Most patients had a fair degree of CVD risk factor 
knowledge; however, key concepts were not understood, such as the effect of increasing 
age on increased cardiovascular risk. The perceived risk of CVD was weakly associated 
with estimated risk, even when controlling for the age of the participant. However, the 
level of cardiovascular risk factor knowledge was not predictive of perceived risk of 
cardiovascular disease. Implications and further discussion of these findings will be 
addressed in the following chapter.  
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CHAPTER 5  
Discussion 
The purpose of this study was to describe the estimated and perceived risk of 
CVD and the level of risk factor knowledge in HIV-infected adults. Additionally, it 
described the relationship between estimated and perceived risk, and examined the 
influence of risk factor knowledge on perceived risk of CVD. The Health Belief Model 
was used to guide this study. This chapter will discuss and analyze the study findings that 
were presented in the previous chapter and will comment on the usefulness of the model 
as a framework for this study. Also, study limitations, implications for nursing practice, 
and directions for future research will be discussed.  
The Changing Paradigm of HIV Care 
Numerous studies suggest that HIV-infected adults on ART have lower rates of 
morbidity and mortality related to HIV infection and that survival is comparable to that of 
the general population (Bhaskaran et al., 2008; Lewden et al., 2007). Moreover, it is 
estimated that by 2015 more than half of those infected with HIV will be greater than 50 
years of age (Effros et al., 2008). The participants in this study had a mean age of 48 
years and had been HIV-infected, on average, for more than 14 years, suggesting that 
many had been infected in the mid-1990s. During this period, the epidemic was at its 
peak; drug development research was intense, and combination therapy was introduced, 
quickly becoming the standard of care. The prevalence of persons living with HIV 
increased steadily and deaths due to AIDS decreased significantly. In this study, 87% of 
participants were taking ART successfully, had a mean CD4 count greater than 500, and 
had good adherence; nearly two-thirds (71.5%) of participants had an undetectable HIV 
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viral load. These data exemplify the concept of HIV as a chronic illness and reinforce the 
need to direct more attention to the management and prevention of comorbidities that are 
more prevalent in the general population, such as cardiovascular disease.  
Prevalence of CVD Risk Factors 
In this study, traditional risk factors that were strong contributors to the elevated 
risk of CVD were smoking, elevated BMI, and prehypertension. The contribution of such 
risk factors to an increased risk of CVD in the HIV-infected population is well 
documented (Friis-Moller et al., 2003; Glass et al., 2006; Kaplan et al., 2007). 
Smoking. In this study, current smoking was reported by 56% of participants, 
with a mean number of cigarettes per day of ten. In the general population, smoking 
prevalence is approximately 21% (U.S. Centers for Disease Control and Prevention, 
2010). In the literature, the rate of smoking noted in the HIV-infected population is often 
substantially higher than the general population (Benard et al., 2007; Burkhalter, 
Springer, Chhabra, Ostroff, & Rapkin, 2005; Capilli, Anastasi, & Ogedegbe, 2011; 
Cockerham et al., 2010; Crothers et al., 2009; Friis-Moller et al., 2003; Glass et al., 2006; 
Kaplan et al., 2007; Mamary, Bahrs, & Martinez, 2002; Sterne et al., 2007). In the D:A:D 
study, the rate of current or previous smokers was 56% (Friis-Moller et al., 2003), which 
was related to a relative risk for MI that was twice that of the nonsmokers. Similarly, the 
Swiss Cohort found that current smoking was the most common CVD risk factor with a 
reported prevalence of 57% (Glass et al., 2006). Crothers et al. (2009) found that in a 
group of HIV-infected veterans, smoking was associated with an increased risk for 
mortality when compared to HIV-infected never smokers (RR 2.31, 95% CI 1.53–3.49, p 
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< .05). These data highlight the importance of addressing smoking cessation efforts in 
this group of individuals in the clinical setting. 
Smoking cessation programs and clinical protocols often exclude participants 
with chronic illnesses, such as HIV infection. In our study, less than 8% of smokers 
reported being currently involved in smoking cessation efforts. However, several studies 
have demonstrated that HIV-infected smokers express a willingness to attempt smoking 
cessation. Mamary et al. (2002) found that two-thirds of current smokers in an urban HIV 
clinic setting were currently thinking about quitting smoking. Burkhalter et al. (2005) 
found that 42% of HIV-infected smokers were in the precontemplation stage of readiness, 
40% were currently contemplating smoking cessation, and 18% were preparing to quit 
smoking. Benard found that 40% of current smokers were motivated to quit smoking. 
Often, a psychiatric comorbidity, such as depression, or the use of illicit drugs or alcohol, 
occurs in tandem with smoking in the HIV-infected population (Benard et al., 2007; 
Burkhalter et al., 2005).   
The development of comprehensive smoking cessation programs for HIV-infected 
adults is critical to reduce the prevalence of current smoking and subsequently reduce 
cardiovascular risk in this population. Interestingly, 97% of participants in this study 
were aware that smoking was a risk factor for CVD. Programs that address depression, 
drug and alcohol use, and smoking cessation may be the most effective. Self-efficacy has 
been found to be a factor related to the success in these efforts (Lloyd-Richardson et al., 
2008; Vidrine, Arduino, Lazev, & Gritz, 2006). Practical programs that can be 
incorporated into the clinical visit and focus on the specific needs of HIV-infected 
smokers are greatly needed. 
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BMI. A body mass index of greater than 25 is consistent with being overweight. 
In this study, the mean BMI was 27, and 58.5% of participants had a BMI of greater than 
25. In a study designed to evaluate cardiovascular risk factors and Framingham Risk 
Scores among HIV-infected men and women, Kaplan et al. (2007) reported that more 
than 40% of men and more than 60% of women with HIV had BMIs greater than 25. 
Also, he found that being overweight was associated with an increased estimated CVD 
risk (measured by FRS). Similarly, Capilli et al. (2011) and Janiszewski et al. (2011) 
found that having a BMI greater than 25 was found to be associated with a higher waist 
circumference; and this was associated with increased cardiovascular risk in HIV-
infected adults (Janiszewski et al., 2011). Dube et al. (2010) did not find an association 
between BMI and endothelial dysfunction (often a marker for increased CVD risk); 
however, a higher BMI has been related to the development of metabolic syndrome and 
diabetes mellitus, which are both associated with increased cardiovascular risk. Mangilli 
et al. (2007) found that the presence of metabolic syndrome in HIV-infected adults was 
associated with increased common c-IMT scores and coronary artery calcium scores.  
Studies examining the effect of weight loss and exercise on cardiovascular risk in 
HIV-infected adults are lacking. One prospective study in overweight adults in the 
general population supported that weight loss through diet and exercise over an 18-month 
period could effect change in weight and significantly reduced cardiovascular risk, 
measured by Framingham Risk Scores (RR 0.86, CI 0.81–0.91, p < .001; Maruthur, 
Wang, & Appel, 2009). Tailored exercise and weight loss intervention studies designed 
for HIV-infected adults to reduce BMI and waist circumference could potentially lower 
the risk for metabolic syndrome, diabetes, and cardiovascular disease in these patients. 
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Prehypertension. Prehypertension, defined as a blood pressure of 120–139 
systolic or 80–89 diastolic, is highly prevalent in the United States, affecting 
approximately 70 million individuals (Chobanion et al., 2003). Prehypertension, as a 
diagnosis, was identified in 2003 by the JNC7 report and was introduced to designate 
individuals who may be at increased risk for the development of cardiovascular disease 
(Chobanion, 2006). In this cohort, 48.5% of participants had a mean blood pressure 
consistent with a diagnosis of prehypertension. In the general population, prehypertension 
prevalences of up to 40% have been reported (Chobanian, 2006; Chobanian et al., 2003; 
Hernandez & Anderson, 2011). Furthermore, individuals with prehypertension have been 
found to have increased Framingham Risk Scores (Qureshi, Suri, Kirmani, Divani, & 
Mohammad, 2005), and were more likely to develop CVD (Vasan et al., 2001). One 
cross-sectional study conducted in Brazil identified that age, male gender, and elevated 
BMI were associated with prehypertension in HIV-infected adults (Roque de Arruda 
Junior et al., 2010). An abstract presented at the Conference on Retroviruses and 
Opportunistic Infections (CROI) in Seattle in March 2012 presented evidence that in a 
Veterans Health Administration study, prehypertension in HIV-infected adults was 
associated with a relative risk of MI of 1.88 (CI 1.19–2.99) when compared to HIV-
negative controls (Armah et al., 2012). Management of prehypertension focuses on 
lifestyle modification—namely reduction of weight, adoption of a DASH diet, reduction 
in dietary sodium, increase in physical activity, and reduction of alcohol consumption. 
Current evidence demonstrates that reduction of blood pressure levels to within the 
normal range through middle age substantially reduces lifetime cardiovascular risk 
(Chobanian, 2006; Chobanian et al., 2003). This is an important consideration for the 
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clinical care of HIV-infected adults, and it may be important for future clinical research 
to modify CVD risk. 
Estimated Risk/Framingham Risk Score (FRS) 
This cohort of HIV-infected adults without a previous history of cardiovascular 
disease had a mean FRS of 7.9, a score that is consistent with the upper limit of low risk 
(defined as a FRS less than 10%). Lo et al. (2010), De Socio et al. (2007), and Falcone et 
al. (2011) reported similar results (mean FRS 7.7 ± 5.1, mean age 46.5; mean FRS 7.0 ± 
5.0, mean age 43.0; and mean FRS 7.0 ± 5.2, mean age 44, respectively) in HIV-infected 
men and women. When participants were stratified into FRS categories, it was noted that 
32% of this sample had Framingham Risk Scores consistent with moderate and high risk. 
Several large cross-sectional studies reported that 14–33% of HIV-adults met criteria for 
moderate risk (Glass et al., 2006; Hadigan et al., 2003; Sayler et al., 2006) and 3–12% 
met criteria for high risk (Bergesen et al., 2004; Glass et al., 2006; Law et al., 2006). 
Studies suggest that the FRS, which was not developed for HIV-infected adults, may not 
be a reliable measure of CVD risk for this population and suggest that it underestimates 
the risk of MI in individuals on antiretroviral therapy (Law et al., 2006). This implies that 
a significant percentage of HIV-infected adults have a considerable 10-year risk of 
having a CVD event and these individuals may be at even higher risk than is actually 
predicted by the FRS. These data have substantial implications for the management of 
adults with HIV infection. Lifestyle modification and the development of preventive 
therapeutic interventions may be advantageous. 
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CVD Risk Factor Knowledge 
The mean CVD knowledge score in this study, using the HDFQ, was 19 (76%). 
Generally, a score of less than 70% is considered a failure on a standardized test. Nearly 
one-third of participants (27.7%) had a score less than 70%. Knowledge scores did not 
differ by age, gender, years living with HIV infection, or years of education. CVD 
knowledge had not previously been measured in an HIV-infected cohort. In diabetics, the 
mean knowledge score using the same instrument was 20.4, and significant differences 
by ethnic group were reported (Wagner et al., 2006). Female gender, higher education, 
and having health insurance was predictive of higher HDFQ scores. This study had a 
much larger sample size (N = 678), older cohort (mean age = 53.7), and was 62% female; 
92% had health insurance, and only 4% of participants had less than a high school 
education. In a study of over 3,000 participants with a history of ischemic heart disease, 
Dracup et al. (2008), using a different scale, reported a mean CVD knowledge score of 
71%. 
The mean knowledge score in this study is fairly high considering that the cohort 
was younger, had a higher percentage of non-high school graduates, and more men. This 
level of risk factor knowledge may be attributed to rigorous public health campaigns such 
as the American Heart Association’s Go Red for Women campaign (American Heart 
Association, 2007) to recognize heart disease in women, and more recently, the 
Department of Health and Human Services Million Hearts and Heart Truth initiatives 
(DHHS, 2011). Despite the level of knowledge reported in this study though, more than 
three quarters of participants reported that they had never discussed heart disease with 
their health care providers.  
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 When individual items on the knowledge scale were examined, it was notable that 
approximately 97% of participants knew that smoking and being overweight were risk 
factors for heart disease. Furthermore, more than 90% knew that a high cholesterol, high 
fat diet, and lack of exercise could contribute to an increased risk for heart disease. Diet 
and exercise were not addressed in this study; however, smoking cessation was, and few 
participants reported being involved in efforts to stop smoking, inferring that knowledge 
alone is not an adequate motivator for behavior change. In several studies examining 
cardiovascular health-promoting behaviors, perceived barriers, perceived susceptibility, 
and self-efficacy were most significantly correlated with adoption of new behaviors 
(Janz, 1988; Janz & Becker, 1984; Wilson et al., 1997). Knowledge was a significant 
predictor in one HIV prevention study examining condom use, but this is more skill-
related than health knowledge (Volk & Koopman, 2001). Efforts to broaden CVD risk 
factor knowledge and more importantly to link risk factor knowledge to risk perception 
and health-related consequences are needed. 
Correlation Between Estimated and Perceived Risk of CVD 
A significant, though weak, positive correlation was found between estimated and 
perceived risk of cardiovascular disease (r = .24). Perceived risk of CVD had not been 
previously measured in the HIV-infected population. In the general population, one study 
found that 40% of diabetic patients were unable to give an estimate of CVD risk, and 
agreement between risk perception and clinical data was weak (Martell-Claros et al., 
2011). Alwan et al. (2009) had similar findings with only half of participants able to 
provide an estimate of their perceived risk, and the ability to do so was associated with 
higher socioeconomic status (Alwan et al., 2009). Homko et al. (2010) found that there 
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was no relationship between actual and perceived risk in a group of 211 adults with Type 
2 diabetes (Homko et al., 2010). Barnhart et al. (2009) reported that perceived risk and 
actual risk were significantly correlated with a similar strength correlation (r = .22), as we 
found in our study. Age was not found to be associated with ability to perceive risk in any 
of these studies, so it is not surprising that we did not find this association either.  
When the study sample was divided by age, it was found that for participants over 
40 years, the correlation was weaker (r = .14), but for participants less than 40 years, the 
correlation became much stronger (r = .46). This seems counterintuitive but can be 
explained by two factors—the variability in the over-40 age group was lower; hence a 
lower correlation. Also, there was an outlier in the PRHDS score in the over-40 age 
group, again contributing to the lower correlation. 
Influence of Knowledge on Perceived Risk of CVD 
The final aim of this study was to examine the influence of CVD risk factor 
knowledge on perceived risk of CVD. Results of this study demonstrated that in HIV-
infected adults, risk factor knowledge was not predictive of perceived risk of CVD. 
Previous studies in the HIV population have not been done. Often though in other 
populations, such as adults with Type 2 diabetes, knowledge has been predictive of risk 
(Choi et al., 2008; Homko et al., 2010). Also, the relationship between knowledge and 
perceived risk is suggested in the Health Belief Model. However, several studies using 
the Health Belief Model failed to demonstrate this relationship (Becker & Levine, 1987; 
Hart, 2005).  
This author suggests that the HIV-infected population is inherently different from 
other populations, such as diabetics or women, with respect to perception of 
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cardiovascular risk for a historical reason. During its first 20 years in the United States, 
HIV was closely associated with mortality due to the lack of effective treatments. Until 
the early 1990s, most individuals diagnosed with this disease developed AIDS and 
eventually died, often within a short period of time. Other chronic illnesses such as 
diabetes do not share this same history. So by nature of history, individuals with HIV are 
different in their perspective and perceptions. In this study, the mean age was 48 years 
and the mean years of HIV infection were 14.7, so this sample consists of individuals to 
whom the epidemic’s history is well known. 
Paterson (2001) has proposed the Shifting Perspectives Model of Chronic Illness, 
a midrange theory that describes what it is like for individuals who live with chronic 
illnesses and offers an explanation of behavior. The model suggests that individuals 
living with a chronic illness are “continually shifting between the perspectives of 
wellness in the foreground and illness in the foreground in order to make sense of” their 
world at any given time (Paterson, 2001, p. 988). Having the perspective of illness in the 
foreground is consuming, and the individual is focused on the condition itself, the 
symptoms, the burden of self-care, and the potential negative outcomes associated with 
the illness. In this perspective, the individual is unable to perceive of concepts associated 
with wellness, may lack motivation for health promotion and prevention activities, or be 
uninterested in preventing events that may occur in the future. HIV-infected adults may 
have an illness in the foreground perspective and, for this reason, a focus on perception of 
risk for CVD is inconceivable for them.  
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Utility of the Health Belief Model 
The Health Belief Model is a predictive model of behavior change, and it was 
used in this descriptive study to describe concepts and potential relationships related to 
cardiovascular risk in HIV-infected adults. The study did not support the relationships 
suggested by the Health Belief Model. In the model, knowledge, age, gender, 
race/ethnicity, and education level are all sociodemographic and structural variables that 
are supposed to influence perceived risk. In this study, none of these relationships were 
found. Several reasons may explain this. Concepts within the model are not clearly 
defined and may be operationalized differently across studies leading to difficulty when 
attempting to observe clear relationships and associations between the concepts. The 
development of standardized scales to measure constructs in the model may facilitate 
measurement and interpretation of results, and allow comparison of findings across 
studies.  
In this study, the correlation between estimated and perceived risk was weak. This 
is consistent with the literature—the model is often criticized because the variables 
proposed in the model correlate weakly with each other and effect sizes were often small, 
r < .21 (Armitage & Conner, 2000). Rosenstock, the developer of the model, attributed 
the lack of predictability, small effect size, and low level of variance to the exclusion of 
the self-efficacy variable, and therefore included self-efficacy in a later version of the 
model. Since it is a predictive model, the Health Belief Model is probably best utilized as 
the theoretical framework for an intervention study, measuring and examining all 
potential predictors of behavior change over time. 
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Study Limitations 
This study has some limitations. The use of a convenience sample and the cross-
sectional nature of the study may have been limiting factors. Patients who felt they were 
not at risk or, conversely, were at high risk may have self-selected to not participate. 
Also, the sample consisted of patients who were actively engaged in care and may be 
different from those not seeking care. Data were collected by interview and therefore may 
have been affected by recall and social desirability bias. Also, the findings may not be 
generalizable to all patients infected with HIV since this study excluded individuals with 
known CVD and those who did not speak and understand English.  
The instruments that were used in this study to measure perceived risk (developed 
for primary care patients in Jordan) and risk factor knowledge (developed for diabetic 
patients) were not developed for HIV-infected patients. Although they demonstrated 
good reliability in this study, they may not have been sensitive or specific enough to 
detect strong associations between the variables under study. Also, the Framingham Risk 
Score was not developed for individuals with HIV infection, and its reliability with this 
population is not known.  
Study Strengths 
This is the first study to measure cardiovascular risk factor knowledge and 
perceived risk of cardiovascular disease in HIV-infected adults in a clinic setting. The 
sample was heterogeneous, with 58.5% from ethnic and racial minorities. Additionally, 
use of the interview method for data collection resulted in a very low rate of missing data 
(less than 5%).  
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Implications for Research and Practice 
This study supports the need to develop innovative programs to reduce 
cardiovascular risk in HIV-infected adults. The high prevalence of smoking highlights the 
need to have tailored interventions to assist this population in its smoking cessation 
efforts. Often, smoking cessation programs and research protocols have strict inclusion 
and exclusion criteria and exclude those with chronic illnesses, such as HIV infection. 
The development of smoking cessation trials specifically designed to meet the needs of 
the HIV-infected patient are much needed. 
 This study provides evidence that there is a need to develop reliable and valid 
instruments that will accurately measure perceived risk of CVD, CVD risk factor 
knowledge, and estimated (actual) risk of CVD in HIV-infected adults. The PRHDS scale 
contained items that were poorly understood by some participants with lower literacy or 
education levels and may need to be rewritten to include simpler language. The HDFQ 
had several items that were focused on heart disease risk factors in diabetic adults that 
may have not been applicable to this population. An instrument to measure CVD risk 
factor knowledge in HIV-infected patients may be a more accurate measure of knowledge 
in this group of adults. The literature suggests that the FRS underestimates risk of disease 
in HIV-infected adults and, until an HIV-specific risk equation is developed and 
validated, prediction of risk in this population may be imprecise.  
Finally, the study supports the need to develop education programs to improve 
cardiovascular risk factor knowledge in this population, especially focusing on the role 
that advancing age, hypertension, obesity, and hyperlipidemia play in increasing 
cardiovascular risk. General CVD risk factor knowledge in this cohort was fairly high, 
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but it was not found to influence perception of risk. Perhaps HIV-infected adults do not 
personalize the general knowledge that they have about heart disease. Perhaps specific 
messages and interventions tailored to the individual in the clinical setting are needed. 
Calculating Framingham Risk Scores during clinical visits for each patient may help to 
personalize the information about CVD risk and increase their perception of risk for heart 
disease. 
Conclusion 
This study examined perceived risk of cardiovascular disease and knowledge of 
cardiovascular risk factors in HIV-infected adults. Findings suggest that HIV-infected 
adults are at risk for developing cardiovascular disease due to the high prevalence of 
traditional cardiovascular risk factors, such as smoking and elevated blood pressure. 
However, the study demonstrated that this group of individuals does not have a high level 
of risk factor knowledge and, more importantly, their level of knowledge did not 
influence their perception of risk for cardiovascular disease. As HIV-infected adults 
continue to age due to the advances in HIV treatment, researchers and health care 
providers will face the challenge of finding effective methods to estimate cardiovascular 
risk, assess risk perception, increase patients’ level of risk factor knowledge, and 
ultimately develop interventions to effect behavior change, reduce risk, and improve 
cardiovascular health in this population.  
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Appendix A 
Data Collection Instrument 
 
Study ID #:  ______________________________   DATE: ________________ 
 
Site:     (1) RI Hospital  (2) Miriam Hospital 
 
Interviewer:  (1) Principal Investigator  (2) Research Assistant 
 
Age: ______ years 
 
Gender:  (1) female (2) male 
 
Employment Status:  (1) employed  (2) unemployed 
 
Education level:  _______________ # of years completed 
 
Years since HIV diagnosis: ______ years 
 
Race/Ethnicity:  
 
(1) White  
(2) African American   
(3) Hispanic  
(4) Asian American       
(5) Pacific American    
(6) Native American   
(7) Other    
(8) Unknown 
 
Health Insurance: (1) none  (2) private  (3) public 
 
HCV Status:  (0) don’t know/not tested (1) positive (2) negative  
 
Current smoker:  (0) no  (1) yes  (3) unknown 
 
If Yes:  ____________ # of cigs/day  __________ # years smoked 
 
Are you currently engaged in any activities or a program to stop smoking? 
 
 (0) no (1) yes  (2) don’t know 
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Are you currently taking a daily aspirin? 
 
 (0) no  (1) yes  (2) sometimes  (3) don’t know 
 
Are you taking medications for diabetes? 
 
 (0) no   (1) yes   (2) don’t know 
 
Are you currently taking, or have you in the past taken, medications for HIV? 
 
(0) never took HIV medications (naïve) 
(1) currently taking HIV medications (on ART) 
(2) took HIV medications in the past, but not taking currently (on treatment 
interruption) 
 
Have you ever discussed CVD (heart disease) risk with you provider? 
 
 (0) no  (1) yes  (3) don’t know/can’t remember 
 
Family History of CVD:    
 
MI in father   <age 55:    (0) no  (1) yes  (2) unknown 
 
MI in mother <age 65:    (0) no  (1) yes  (2) unknown 
 
 
Diabetes in participant:    (0) no   (1) yes 
 
 
 
Weight: _________ lbs   Height: _____________ Calculated BMI: _____________  
 
 
 
Blood Pressure:  (1) ______________ (2) ______________ (3) __________________ 
 
 
Current Medications: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
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CLINICAL CHART DATA EXTRACTION: 
 
 
Total Cholesterol: ______________ ____ Triglycerides:__________________ 
 
LDL: ____________________________  HDL: _________________________ 
 
Fasting Glucose: ________________________  
 
Current CD4 Count: _____________________ 
 
Nadir CD4 Count:  ______________________ 
 
Current HIV- PVL: ______________________ 
 
Framingham Risk Score: ____________ % risk
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APPENDIX B   
Perception of Risk of Heart Disease Scale (PRHDS) 
 
      Strongly              Strongly 
      Disagree Disagree Agree  Agree 
 
1. There is a possibility that I have        1        2       3      4 
     heart disease. 
 
2. There is a good chance that I will        1        2       3      4  
     get heart disease during the next 
     10 years.  
 
3. A person who gets heart disease         1         2       3           4 
     has no chance of being cured. 
 
4. I have a high chance of getting        1         2       3       4 
    heart disease because of my past 
    behaviors. 
 
5. I feel sure that I will get heart         1         2       3      4 
     disease. 
 
6. Healthy lifestyle habits are          1          2       3      4 
    unattainable. 
 
7. It is likely that I will get heart                1         2        3      4  
     disease. 
 
8. I am at risk for getting heart        1         2      3      4 
     disease. 
 
9. It is possible that I will get         1         2                 3      4 
    heart disease. 
 
10. I am not doing anything now        1         2         3      4 
      that is unhealthy to my heart. 
 
11. I am too young to have heart         1         2       3      4 
      disease. 
 
12. People like me do not get heart        1         2      3           4 
      disease. 
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      Strongly              Strongly 
      Disagree Disagree Agree  Agree 
 
13.  I am very healthy so my body        1          2       3      4 
       can fight off heart disease. 
 
14. I am not worried that I might        1          2       3      4 
      get heart disease. 
 
15. People my age are too young to         1          2       3      4  
      get heart disease. 
 
16. People my age do not get heart         1          2       3       4 
      disease. 
 
17. My lifestyle habits do not put         1          2       3       4 
      me at risk for heart disease. 
 
18. No matter what I do, if I am         1          2       3      4 
      going to get heart disease, I will 
      get it. 
 
19. People who don’t get heart          1          2             3      4 
      disease are just plain lucky. 
 
20. The causes of heart disease are         1           2        3      4 
      unknown. 
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APPENDIX C 
Heart Disease Fact Questionnaire (HDFQ) 
1. A person always knows when they have heart disease.  True False Don’t know 
 
2. If you have a family history of heart disease, you are True False Don’t Know 
at risk for developing heart disease. 
 
3. The older a person is, the greater their risk of having True False Don’t Know 
heart disease. 
 
4. Smoking is a risk factor for heart disease.   True False Don’t Know 
 
5. A person who stops smoking will lower their risk   True False Don’t Know 
of heart disease. 
 
6. High blood pressure is a risk factor for heart disease. True False Don’t Know 
 
7. Keeping blood pressure under control will reduce a  True False Don’t Know                                          
person’s risk for developing heart disease. 
 
8. High cholesterol is a risk factor for developing heart True False Don’t Know 
disease. 
 
9. Eating fatty foods does not affect blood cholesterol  True False Don’t Know 
levels. 
 
10. If your good cholesterol (HDL) is high you are at  True False Don’t Know 
risk for heart disease. 
 
11. If your bad cholesterol (LDL) is high you are at   True False Don’t Know 
risk for heart disease.  
 
12. Being overweight increases a person’s risk for   True False Don’t Know 
heart disease. 
 
13. Regular physical activity will lower a person’s   True False Don’t Know  
 chance of getting heart disease. 
 
14. Only exercising at a gym or in an exercise class  True  False Don’t Know 
 will lower a person’s chance of developing heart 
 disease. 
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15. Walking and gardening are considered exercise   True False Don’t Know    
that will help lower a person’s chance of developing 
heart disease. 
 
16. Diabetes is a risk factor for developing heart disease. True False Don’t Know 
 
17. High blood sugar puts a strain on the heart.  True False Don’t Know 
 
18. If your blood sugar is high over several months it  True False Don’t Know 
can cause your cholesterol level to go up and  
increase your risk of heart disease.  
 
19. A person who has diabetes can reduce their risk of True False Don’t Know 
developing heart disease if they keep their blood sugar  
levels under control.  
 
20. People with diabetes rarely have high cholesterol. True False Don’t Know 
 
21. If a person has diabetes, keeping their cholesterol  True False Don’t Know 
under control will help lower their chance of having  
heart disease. 
 
22. People with diabetes tend to have low HDL (good)  True False Don’t Know 
cholesterol. 
 
23. A person who has diabetes can reduce their risk   True False Don’t Know 
of developing heart disease if they keep their blood  
pressure under control. 
 
24. A person who has diabetes can reduce their risk   True  False Don’t Know 
of developing heart disease if they keep their weight  
under control. 
 
25. Men with diabetes have a higher risk of heart disease  True False Don’t Know 
than women with diabetes. 
 
 
 
 
 
 
